US.PFE · Pfizer

{
  "risk": {
    "level": "Medium",
    "reason": "risk management score >= 6.5/10",
    "position": {
      "score": 1.8,
      "details": {
        "atrPct": 1.9871537535126456,
        "turnoverUsdM": 924.47200135,
        "liquidityPoints": 0.6,
        "volatilityPoints": 1.2
      }
    },
    "rrPoints": 1.4,
    "stopLevels": {
      "symbol": "US.PFE",
      "rr_range": "1:1.0-1:2.5",
      "risk_profile": "中等",
      "stop_loss_price": 23.92,
      "strength_details": {
        "ma_score": 1,
        "atr_score": 2.5,
        "rsi_score": 2,
        "macd_score": 3,
        "volume_score": 1
      },
      "market_adjustment": 1,
      "risk_reward_ratio": 1.3,
      "stop_loss_percent": 4,
      "take_profit_price": 26.1555,
      "target_multiplier": 1.9,
      "technical_strength": 1.92,
      "take_profit_percent": 5
    },
    "positionPoints": 1.8,
    "stopLossPoints": 2.4,
    "diversification": {
      "score": 2,
      "details": {
        "method": "sector concentration proxy; no portfolio holdings used",
        "sector": "Health Care",
        "concentratedSectorPenalty": 0
      }
    },
    "riskRewardRatio": 1.2580808080808081,
    "stopLossPercent": 3.974307507025291,
    "diversificationPoints": 2
  },
  "total": {
    "max": 160,
    "result": 59.3,
    "formula": "score_with_momentum_v2 = main_score + momentum_5d_v2_score",
    "baseScore": 56.3,
    "modelVersion": "cursor_18_27_news_v2_160",
    "momentum5dScore": 3
  },
  "market": {
    "ma20": 24.618,
    "ma50": 25.0978,
    "close": 24.91,
    "prevClose": 25.15,
    "avgVolume20": 39443344,
    "volumeRatio": 0.94,
    "changePercent": -0.95
  },
  "sources": {
    "catalyst": "finnhub_news_keyword_model",
    "sentiment": "finnhub_news_keyword_model",
    "fundamentals": "fmp_stable",
    "institutional": null,
    "marketContext": "twelvedata+fred"
  },
  "barCount": 60,
  "momentum": {
    "max": 50,
    "result": 3,
    "details": {
      "ret_5d": -0.003998400639744104,
      "max_score": 50,
      "max_total": 50,
      "raw_total": 3,
      "vcp_bonus": 0,
      "vol_ratio": 0.9264923366664187,
      "ret_points": 0,
      "vol_points": 0,
      "range_ratio": 0.9736176539459351,
      "volat_points": 0,
      "day_range_pct": 0.017061421116017692,
      "model_version": "cursor_18_27_news_v2_160",
      "available_bars": 30,
      "breakout_points": 0,
      "partial_history": false,
      "pullback_points": 3,
      "breakout_vol_bonus": 0,
      "first_breakout_20d": false,
      "return_window_days": 5,
      "first_breakout_bonus": 0,
      "breakout_quality_points": 0
    },
    "formula": "Cursor_18.25 5D momentum v2 0-50",
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "scoreMax": 110,
  "composite": {
    "max": 160,
    "result": 59.3,
    "formula": "Cursor_18.25 ranking score v2 (score_with_momentum_v2)",
    "weights": [
      {
        "raw": 2.8,
        "label": "基本面",
        "weight": "5/110",
        "normalized": 56,
        "contribution": 2.8
      },
      {
        "raw": 10.8,
        "label": "資金流",
        "weight": "20/110",
        "normalized": 54,
        "contribution": 10.8
      },
      {
        "raw": 9,
        "label": "市場環境",
        "weight": "15/110",
        "normalized": 60,
        "contribution": 9
      },
      {
        "raw": 2,
        "label": "催化劑",
        "weight": "20/110",
        "normalized": 10,
        "contribution": 2
      },
      {
        "raw": 7.6,
        "label": "風險管理",
        "weight": "10/110",
        "normalized": 76,
        "contribution": 7.6
      },
      {
        "raw": 20.1,
        "label": "技術信號",
        "weight": "30/110",
        "normalized": 67,
        "contribution": 20.1
      },
      {
        "raw": 4,
        "label": "情緒分析",
        "weight": "10/110",
        "normalized": 40,
        "contribution": 4
      }
    ],
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "momentumMax": 50,
  "scoreStatus": "checked",
  "standard110": {
    "rating": "觀望",
    "result": 56.3,
    "details": [
      "基本面分析總分: 2.8/5分",
      "資金流分析總分: 10.8/20分",
      "市場環境分析總分: 9/15分",
      "催化劑分析: 2/20分",
      "風險管理總分: 7.6/10分",
      "技術信號分析總分: 20.1/30分",
      "情緒分析: 4/10分",
      "共振率(僅顯示不加分): 0%"
    ],
    "formula": "基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10",
    "dimensionScores": {
      "催化劑": 2,
      "基本面": 2.8,
      "資金流": 10.8,
      "市場環境": 9,
      "情緒分析": 4,
      "技術信號": 20.1,
      "風險管理": 7.6
    },
    "dimensionDetails": {
      "催化劑": {
        "max": 20,
        "grade": "較差",
        "items": {
          "catalyst": {
            "score": 2,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "catalystCount": 0
            }
          },
          "catalystPoints": 2
        }
      },
      "基本面": {
        "max": 5,
        "grade": "較差",
        "items": {
          "pbPoints": 0.5,
          "pePoints": 0.5,
          "epsPoints": 0,
          "roePoints": 0,
          "debtPoints": 0.4,
          "marginPoints": 0,
          "turnoverUsdM": 924.47200135,
          "volumePoints": 0.5,
          "revenuePoints": 0,
          "dividendPoints": 0.4,
          "marketCapPoints": 0.5
        },
        "source": "fmp_stable"
      },
      "資金流": {
        "max": 20,
        "grade": "較差",
        "items": {
          "cmfPoints": 0.8,
          "mfiPoints": 3.2,
          "obvPoints": 0.8,
          "vwapPoints": 4,
          "institutional": {
            "score": 2,
            "details": {
              "source": "optional-neutral",
              "warning": {
                "code": "INSTITUTIONAL_DATA_OPTIONAL",
                "symbol": "US.PFE",
                "message": "Institutional ownership is unavailable; neutral 2/4 money-flow treatment used."
              },
              "optional": true,
              "holderCount": null,
              "holderPoints": 2,
              "top10ShareRatio": null,
              "concentrationPenalty": 0
            }
          },
          "institutionPoints": 2
        }
      },
      "市場環境": {
        "max": 15,
        "grade": "一般",
        "items": {
          "vix": {
            "score": 1.8,
            "details": {
              "source": "twelvedata+fred",
              "vixClose": 20.66
            }
          },
          "trend": {
            "score": 0.8,
            "details": {
              "qqq": {
                "ma20": 702.2489964000001,
                "ma50": 715.3588015999999,
                "name": "QQQ",
                "close": 683.54999,
                "points": 0.4
              },
              "spy": {
                "ma20": 745.5820062000001,
                "ma50": 744.7240025799999,
                "name": "SPY",
                "close": 741.69,
                "points": 0.4
              },
              "source": "twelvedata+fred"
            }
          },
          "atrPct": 1.9871537535126456,
          "atrPoints": 4,
          "cciPoints": 2.4,
          "vixPoints": 1.8,
          "marketTrendPoints": 0.8
        }
      },
      "情緒分析": {
        "max": 10,
        "grade": "較差",
        "items": {
          "sentiment": {
            "score": 4,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "negativeHits": 0,
              "positiveHits": 2,
              "sentimentScoreRaw": 0.6
            }
          },
          "sentimentData": {
            "raw": [
              {
                "id": 141066824,
                "url": "https://finnhub.io/api/news?id=89b5c63ec88735358783b4417d24d913bb8e3af2493b1710f55e6f511f5d9593",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Beyond analysts' top-and-bottom-line estimates for Pfizer (PFE), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2026.",
                "category": "company",
                "datetime": 1785417308,
                "headline": "Pfizer (PFE) Q2 Earnings Preview: What You Should Know Beyond the Headline Estimates"
              },
              {
                "id": 141064530,
                "url": "https://finnhub.io/api/news?id=233fa555eedd7625f54a5a375e9d86e540fc0826aa6fc15d56294a428e47e9ff",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Pfizer (NYSE:PFE) and Eli Lilly and Company (NYSE:LLY) offer unique divergent investment opportunities in the pharmaceutical industry. While one acts as a value and income play, the other stands out as a solid growth investment supported by rapid expansion in obesity and diabetes franchises. Pfizer Value Investment Play Pfizer (NYSE:PFE) has seen its valuation drop […]",
                "category": "company",
                "datetime": 1785410352,
                "headline": "Pfizer Inc. (PFE) vs. Eli Lilly and Company (LLY): The Growth vs. Value Play in Pharma"
              },
              {
                "id": 141062283,
                "url": "https://finnhub.io/api/news?id=eeb880b154f2133b229ca2516bcc18f6e80f732123551aa2b674b87e2e835595",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "European Commission grants marketing authorization for Pfizer and BioNTech’s XFG-adapted COVID-19 vaccine for the 2026-2027 season in the EU. Approval covers use in individuals aged 6 months and older across all EU member states. Authorization supports advance manufacturing and supply ahead of the upcoming respiratory disease season. Pfizer, listed as NYSE:PFE, now has European Commission authorization for its XFG-adapted COVID-19 vaccine for the 2026-2027 season. The decision confirms that...",
                "category": "company",
                "datetime": 1785381497,
                "headline": "Pfizer (PFE) Wins EU Approval For Updated COVID Vaccine Ahead Of 2026 Season"
              },
              {
                "id": 141048339,
                "url": "https://finnhub.io/api/news?id=b49d4ea2a31e3d033eefa05b22ae138be9ffc060ec5e6b7a313c08e900216287",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "In the most recent trading session, Pfizer (PFE) closed at $25.25, indicating a +2.35% shift from the previous trading day.",
                "category": "company",
                "datetime": 1785275104,
                "headline": "Pfizer (PFE) Surpasses Market Returns: Some Facts Worth Knowing"
              },
              {
                "id": 141043613,
                "url": "https://finnhub.io/api/news?id=40990baf1b73620c80138e2cefd638ab9f0b8ee3c0eb323e7f8610f9347c1f7c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Pfizer (PFE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
                "category": "company",
                "datetime": 1785247218,
                "headline": "Pfizer (PFE) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release"
              },
              {
                "id": 141031624,
                "url": "https://finnhub.io/api/news?id=9710488e858f7bc3496d73e316c57f57eef4c08c71788d8128fb3b79243512b1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Earlier this month, Pfizer announced that the FDA accepted for Priority Review a supplemental application for TALZENNA in combination with XTANDI to treat men with HRR gene‑altered metastatic castration‑sensitive prostate cancer, supported by positive Phase 3 TALAPRO‑3 results and existing approvals for later‑stage disease. This move could broaden Pfizer’s prostate cancer franchise into an earlier disease setting, potentially deepening its footprint in precision oncology and expanding the...",
                "category": "company",
                "datetime": 1785143662,
                "headline": "Did FDA’s Priority Review of TALZENNA plus XTANDI in Earlier Prostate Cancer Just Shift Pfizer's (PFE) Investment Narrative?"
              },
              {
                "id": 140997786,
                "url": "https://finnhub.io/api/news?id=4dfdaca076fed8bec348354807b21ff775ca5e0fd371341cfb52ac26d5bb3e93",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Pfizer's Talzenna plus Xtandi combo wins FDA priority review for HRR gene-mutated metastatic castration-sensitive prostate cancer.",
                "category": "company",
                "datetime": 1784821920,
                "headline": "PFE's Talzenna sNDA Gets FDA Priority Tag in Wider Prostate Cancer Use"
              },
              {
                "id": 140988040,
                "url": "https://finnhub.io/api/news?id=27d142416c421d2f8497bbc1fc5ac31113ce033af1c8d854492bfb33262d5f21",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Pfizer (PFE) is back in focus after Arbutus Biopharma and Genevant Sciences expanded their patent litigation over mRNA lipid nanoparticle technology, adding new international cases that raise legal and operational questions for the company’s COVID-19 vaccine business. See our latest analysis for Pfizer. The legal headlines around Pfizer’s mRNA vaccine coincide with a mixed price pattern, with the stock showing a 1-day share price return of 0.77% and a 7-day share price return of 2.85%, but a...",
                "category": "company",
                "datetime": 1784754525,
                "headline": "Pfizer (PFE) Faces Expanded Vaccine Lawsuits On A Fair Value Narrative That Still Sees Upside"
              }
            ],
            "raw_source": [
              {
                "id": 141071590,
                "url": "https://finnhub.io/api/news?id=1e5627f917fac740cfaa8152f51422d6c0b7377652e2f326899f3c213533e948",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "The RNA-focused biotech shed 30% of its market value — or close to $12 billion — amid growing investor concerns about its main drug business.",
                "category": "company",
                "datetime": 1785427920,
                "headline": "Alnylam plunges as earnings deliver ‘one-two punch’"
              },
              {
                "id": 141066701,
                "url": "https://finnhub.io/api/news?id=6c58f0d6da027f5209d141c1ef2370eb95d32ae48782c108da3d5b120b00ed88",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Rinvoq, Comirnaty and Opzelura have all received their own EC approvals this week.",
                "category": "company",
                "datetime": 1785423940,
                "headline": "EU regulatory roundup: AbbVie, Pfizer & BioNTech and Incyte net approvals"
              },
              {
                "id": 141066698,
                "url": "https://finnhub.io/api/news?id=28e84711ad50dbfa85fde88ffbe2fc182ef5443874fddc18240fc84ca85a8d84",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Bristol Myers Squibb faces declining revenue in its legacy drug portfolio, but new products like Opdivo are offsetting the drop.",
                "category": "company",
                "datetime": 1785420660,
                "headline": "Bristol Myers Stock Rises. Why the Drugmaker Is Lifting Its Earnings Guidance."
              },
              {
                "id": 141066824,
                "url": "https://finnhub.io/api/news?id=89b5c63ec88735358783b4417d24d913bb8e3af2493b1710f55e6f511f5d9593",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Beyond analysts' top-and-bottom-line estimates for Pfizer (PFE), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2026.",
                "category": "company",
                "datetime": 1785417308,
                "headline": "Pfizer (PFE) Q2 Earnings Preview: What You Should Know Beyond the Headline Estimates"
              },
              {
                "id": 141065556,
                "url": "https://finnhub.io/api/news?id=e075b1faf07aeb835674f40e1c976a29cdb9d8fc6813eb8d03a2f7cb5f50266e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Strong sales of blood thinner Eliquis and newer drugs Camzyos and Reblozyl pushed second-quarter revenue to $12.97 billion, above analyst estimates",
                "category": "company",
                "datetime": 1785413829,
                "headline": "Bristol Myers Squibb raises 2026 forecast after Q2 earnings beat"
              },
              {
                "id": 141069226,
                "url": "https://finnhub.io/api/news?id=523450f9bf2cd1851e4858c410b6e281acaa27d4d016dd1cf46e97f21b59c8dc",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/30/Pfizer-Inc.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "PFE",
                "summary": "Pfizer reports Phase 3 data for LITFULO in treating nonsegmental vitiligo and plans to submit global regulatory filings.",
                "category": "company",
                "datetime": 1785413075,
                "headline": "Pfizer Prepares Global Regulatory Litfulo Filings Following Skin Pigment Improvements In Late-Stage Trials"
              },
              {
                "id": 141064530,
                "url": "https://finnhub.io/api/news?id=233fa555eedd7625f54a5a375e9d86e540fc0826aa6fc15d56294a428e47e9ff",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Pfizer (NYSE:PFE) and Eli Lilly and Company (NYSE:LLY) offer unique divergent investment opportunities in the pharmaceutical industry. While one acts as a value and income play, the other stands out as a solid growth investment supported by rapid expansion in obesity and diabetes franchises. Pfizer Value Investment Play Pfizer (NYSE:PFE) has seen its valuation drop […]",
                "category": "company",
                "datetime": 1785410352,
                "headline": "Pfizer Inc. (PFE) vs. Eli Lilly and Company (LLY): The Growth vs. Value Play in Pharma"
              },
              {
                "id": 141064449,
                "url": "https://finnhub.io/api/news?id=809e5299d9985a6bf15571958e544026b0ae39e40f7dfe0e8569e9dbe1160064",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Bristol Myers Squibb faces declining revenue in its legacy drug portfolio, but new products like Opdivo are offsetting the drop.",
                "category": "company",
                "datetime": 1785410040,
                "headline": "Bristol Myers Raises Earnings Guidance as Newer Drugs Drive Big Quarterly Beat"
              },
              {
                "id": 141064624,
                "url": "https://finnhub.io/api/news?id=4115b5fb9cbdc4e9cca043f993682509728771accda7158bf24bfe059406d225",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "NEW YORK, July 30, 2026--Pfizer Inc. (NYSE: PFE) today announced positive topline results from two Phase 3 trials evaluating the efficacy and safety of LITFULO once daily in patients with both active and stable nonsegmental vitiligo (NSV) and who had a broad range of disease severity. The TRANQUILLO study included patients aged 12 years and older, while TRANQUILLO 2 enrolled adults only. Across the studies, both the 50 and 100 milligram doses of LITFULO delivered significant, clinically meaningf",
                "category": "company",
                "datetime": 1785408300,
                "headline": "Pfizer Announces Positive Topline Phase 3 Results for LITFULO in Patients with Nonsegmental Vitiligo"
              },
              {
                "id": 141065262,
                "url": "https://finnhub.io/api/news?id=58a5360ea0dea00271f77d863842593b6696b448732ec0c7851ca1e68bdfc1ad",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1313668225/image_1313668225.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "PFE",
                "summary": "Bristol-Myers Squibb Company hits a 52-week high on Q2 results, EPS guidance raise, and key drugs’ momentum. Read why BMY stock is a buy.",
                "category": "company",
                "datetime": 1785403803,
                "headline": "Bristol-Myers Squibb: Why I'm Still Bullish After Q2"
              },
              {
                "id": 141069227,
                "url": "https://finnhub.io/api/news?id=4e05816d70a9379e7749c5a3907602280ba4fe962de422f7029232dd09e59994",
                "image": "",
                "source": "Benzinga",
                "related": "PFE",
                "summary": "Phase 3 trials evaluated the efficacy and safety of LITFULO once daily in patients with both active and stable nonsegmental vitiligo (NSV) and who had a broad range of disease severity. The TRANQUILLO study included",
                "category": "company",
                "datetime": 1785394117,
                "headline": "Pfizer Announces Topline Results From Two Phase 3 Trials Of LITFULO In Patients With Vitiligo; Both The 50 And 100 Milligram Doses Delivered Significant, Clinically Meaningful Improvements Over Placebo"
              },
              {
                "id": 141062283,
                "url": "https://finnhub.io/api/news?id=eeb880b154f2133b229ca2516bcc18f6e80f732123551aa2b674b87e2e835595",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "European Commission grants marketing authorization for Pfizer and BioNTech’s XFG-adapted COVID-19 vaccine for the 2026-2027 season in the EU. Approval covers use in individuals aged 6 months and older across all EU member states. Authorization supports advance manufacturing and supply ahead of the upcoming respiratory disease season. Pfizer, listed as NYSE:PFE, now has European Commission authorization for its XFG-adapted COVID-19 vaccine for the 2026-2027 season. The decision confirms that...",
                "category": "company",
                "datetime": 1785381497,
                "headline": "Pfizer (PFE) Wins EU Approval For Updated COVID Vaccine Ahead Of 2026 Season"
              },
              {
                "id": 141058479,
                "url": "https://finnhub.io/api/news?id=20330f9aa63d340023dff15300d33d43f5125ac17930a593ea3f74d6c82f801b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "NEW YORK & MAINZ, Germany, July 29, 2026--Pfizer Inc. (NYSE: PFE, \"Pfizer\") and BioNTech SE (Nasdaq: BNTX, \"BioNTech\") announced today that the European Commission (EC) has granted marketing authorization for the companies’ 2026-2027 COVID-19 vaccine formula, targeting the XFG variant, for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 6 months of age and older. The adaptation is based on the recommendation from the Emergency Task Force (ETF) of the European Medicine",
                "category": "company",
                "datetime": 1785357000,
                "headline": "European Commission Authorizes Pfizer and BioNTech XFG-adapted COVID-19 Vaccine in the European Union"
              },
              {
                "id": 141057017,
                "url": "https://finnhub.io/api/news?id=e2cfd77352aedb0d87503712841214980f53bb4ab61b29927df9b64aee78b575",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "The sticker shock on the pharma giant's shares fades once you look at what investors are paying for the earnings expected just two years from now.",
                "category": "company",
                "datetime": 1785348670,
                "headline": "The Real Price of AbbVie Stock Is Cheaper Than You Think"
              },
              {
                "id": 141057077,
                "url": "https://finnhub.io/api/news?id=4a73e97bf16c01c4763ccc1ac48e9fce315900a166893fe20d536f40103001c1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "MRNA is likely to face a key Q2 test as investors await results, FDA updates on mRNA-1010 and commercialization plans that could shape its post-COVID growth.",
                "category": "company",
                "datetime": 1785344580,
                "headline": "Moderna Q2 Earnings Loom: Buy or Sell the Stock Ahead of Results?"
              },
              {
                "id": 141059117,
                "url": "https://finnhub.io/api/news?id=20ef72221a78ef5348be34c9b465401534570264dc50e4fab31f1b466f8facf4",
                "image": "",
                "source": "Benzinga",
                "related": "PFE",
                "summary": "The formula targets the XFG variant, for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 6 months of age and older. The adaptation is based on the recommendation from the Emergency Task Force",
                "category": "company",
                "datetime": 1785342989,
                "headline": "European Commission Grants Marketing Authorization For Pfizer And BioNTech's 2026-27 COVID-19 Vaccine Formula"
              },
              {
                "id": 141055842,
                "url": "https://finnhub.io/api/news?id=c14e33d7c4c2d53b4ffc79083097214388149fe11afd45afa6067a552f47eaf0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Pfizer heads into Q2 earnings with expectations for growth in key products, COVID headwinds, and guidance updates that could shape its outlook.",
                "category": "company",
                "datetime": 1785338640,
                "headline": "Pfizer Stock Ahead of Q2 Earnings: To Buy or Not to Buy?"
              },
              {
                "id": 141054031,
                "url": "https://finnhub.io/api/news?id=f79e98f0818c7403de7fa168099f007da064e195d777670372f0cf8b6b2cdef0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Lilly (LLY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
                "category": "company",
                "datetime": 1785333626,
                "headline": "Eli Lilly (LLY) Earnings Expected to Grow: Should You Buy?"
              },
              {
                "id": 141053052,
                "url": "https://finnhub.io/api/news?id=88c1da6424e2bcd1687e7851e42c71e12f65861676add5f432ef6e0379d4f99b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Not every fat dividend yield is worth chasing into retirement, and the difference between a durable income stream and a yield trap often hides in details most investors skip past entirely.",
                "category": "company",
                "datetime": 1785330046,
                "headline": "5 High-Yielding Dividend Stocks for Retirees to Buy and Hold Forever"
              },
              {
                "id": 141052957,
                "url": "https://finnhub.io/api/news?id=29f92a30df8ade7e656249e4e4a9b585c76fc2f81dc0788a86ee7f8f3e134c8e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Freehand's AI Agents autonomously manage supply-chain spend for Meta, Unilever, Johnson & Johnson, Dunkin', Pfizer and Cardinal Health. Freehand's AI Agents autonomously manage supply-chain spend for Meta, Unilever, Johnson & Johnson, Dunkin', Pfizer and Cardinal Health among others. Freehand builds autonomous AI agents that run supply-chain spend for the world's largest enterprises — taking on procurement, supplier management, invoice and payment operations across complex categories such as log",
                "category": "company",
                "datetime": 1785330000,
                "headline": "Freehand Raises $75M to Scale AI Teams Managing Supply Chain Spend for Fortune 500 Companies"
              },
              {
                "id": 141052744,
                "url": "https://finnhub.io/api/news?id=ee3d82983ae7a0167ede75201a6bdd0140563121544908e2a83245e2ecba3677",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Retirement means living off your portfolio, not waiting for it to grow, and right now five familiar dividend giants are trading at prices that Wall Street considers deeply undervalued.",
                "category": "company",
                "datetime": 1785328990,
                "headline": "Boomers Are Buying 5 Quality High-Yield Stocks at Big Discounts Hand Over Fist"
              },
              {
                "id": 141048339,
                "url": "https://finnhub.io/api/news?id=b49d4ea2a31e3d033eefa05b22ae138be9ffc060ec5e6b7a313c08e900216287",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "In the most recent trading session, Pfizer (PFE) closed at $25.25, indicating a +2.35% shift from the previous trading day.",
                "category": "company",
                "datetime": 1785275104,
                "headline": "Pfizer (PFE) Surpasses Market Returns: Some Facts Worth Knowing"
              },
              {
                "id": 141047303,
                "url": "https://finnhub.io/api/news?id=556426890a3fac26e5447912eb362cc02010df281b0dcb32f90c4409a7a36c9e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Johnson & Johnson stock's oncology engine and its steady guidance raises were on the record quarters before the price moved.",
                "category": "company",
                "datetime": 1785271965,
                "headline": "What Johnson & Johnson Stock Told You Before It Surged"
              },
              {
                "id": 141047304,
                "url": "https://finnhub.io/api/news?id=964cb7fb943f3d27b92bfa4cd03543b70ad5d97017a3e0c9b5c997db08924eeb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "One of the market's strongest health care performers barely moves with the index you already own, and that gap is the whole point.",
                "category": "company",
                "datetime": 1785271282,
                "headline": "Does Eli Lilly Stock Actually Diversify Your Portfolio?"
              },
              {
                "id": 141045221,
                "url": "https://finnhub.io/api/news?id=aed8f8ea06ef7fad60e0a5b472bd22b69426b946331c27e18ddba12db744ec24",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "AbbVie's two newest drugs are growing so fast they've rewritten the company's entire story, and Wall Street may not have fully priced in what happens when the July 31 earnings report confirms it.",
                "category": "company",
                "datetime": 1785258596,
                "headline": "3 Major Reasons for Investors to Buy AbbVie Stock Before July 31st"
              },
              {
                "id": 141045190,
                "url": "https://finnhub.io/api/news?id=735a43ba3d19c4d05c735bc52ebace2e3812b9e0acdf5d504798b0860483b6e1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Eli Lilly's expanding oncology and newer medicine portfolio is set to play a pivotal role in its Q2 earnings alongside its blockbuster GLP-1 franchise.",
                "category": "company",
                "datetime": 1785251880,
                "headline": "Here's How LLY's Non-GLP-1 Portfolio Is Poised Ahead of Q2 Earnings"
              },
              {
                "id": 141043613,
                "url": "https://finnhub.io/api/news?id=40990baf1b73620c80138e2cefd638ab9f0b8ee3c0eb323e7f8610f9347c1f7c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Pfizer (PFE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
                "category": "company",
                "datetime": 1785247218,
                "headline": "Pfizer (PFE) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release"
              },
              {
                "id": 141042622,
                "url": "https://finnhub.io/api/news?id=135f171cc6aac9a3cd12df053bb808523ab0034822770b6a4a69ff2361ec2ea3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "As the biopharmaceutical industry prepares to convene for Cambridge Healthtech Institute's 18th Annual Bioprocessing Summit, taking place August 10-13, 2026, in Boston, this year's program will focus on one of the industry's most pressing priorities: Transforming Bioprocessing for the Digital Age. Bringing together scientists, engineers, manufacturing professionals, and technology innovators from across the biopharmaceutical ecosystem, the Summit will explore how organizations are embracing digi",
                "category": "company",
                "datetime": 1785240000,
                "headline": "Transforming Bioprocessing for the Digital Age Takes Center Stage at the Bioprocessing Summit 2026"
              },
              {
                "id": 141042399,
                "url": "https://finnhub.io/api/news?id=636e6876032e77d8e72732ddd75f2acb8ecd9a7d6233a757896254532f03b6d4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "DENVER, July 28, 2026--As artificial intelligence reshapes cybersecurity, risk management, and enterprise leadership, organizations are looking for practical strategies—not just predictions—to navigate what's next. From November 4-6, more than 700 executive leaders will gather at the Gaylord Rockies Resort & Convention Center in Denver, Colorado, for the EWF Annual Conference.",
                "category": "company",
                "datetime": 1785240000,
                "headline": "As AI Reshapes Cybersecurity, EWF 2026 Brings Together Industry Leaders to Deliver Practical Solutions"
              },
              {
                "id": 141040317,
                "url": "https://finnhub.io/api/news?id=bba15b502f21075a9d5c4a15cc517ac72f6cab672012538f25aad0191a351da6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "OPKO Health Inc (OPK) reports significant revenue growth in pharmaceuticals and a notable reduction in net loss, despite challenges in diagnostics.",
                "category": "company",
                "datetime": 1785214876,
                "headline": "OPKO Health Inc (OPK) Q2 2026 Earnings Call Highlights: Strong Pharmaceutical Growth and ..."
              },
              {
                "id": 141037135,
                "url": "https://finnhub.io/api/news?id=f039384443066be35bc6ced345a619fa1e6911431bbd02d74d2a8573ae541097",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "The drugmaker's rapid stock gains have led to a premium valuation, forcing investors to question its capacity for future growth.",
                "category": "company",
                "datetime": 1785182092,
                "headline": "The Engine Behind ABBV Stock Has Real Parts"
              },
              {
                "id": 141037196,
                "url": "https://finnhub.io/api/news?id=ff0ecc3beb73f41dca655e7546be35519361d53a3076d755bf3f6b14845a4e77",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "BMY heads into Q2 earnings with growth drugs driving momentum as legacy products decline, setting the stage for a closely watched earnings report.",
                "category": "company",
                "datetime": 1785179280,
                "headline": "Should You Buy, Hold, or Sell BMY Stock Ahead of Q2 Earnings?"
              },
              {
                "id": 141036037,
                "url": "https://finnhub.io/api/news?id=2cc61cdbabe57465c6369f88d1cd57b760ec36da2bc51946d6d2f08f0584f756",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Here is a way to get paid a significant income stream today from Eli Lilly stock, which you keep no matter what, while setting a price far below current levels where you would be willing to buy.",
                "category": "company",
                "datetime": 1785177225,
                "headline": "Collect 9.8% On LLY Stock Now, Own It 30% Cheaper If It Dips"
              },
              {
                "id": 141035245,
                "url": "https://finnhub.io/api/news?id=907644a0468d61ac054182ce249d9a1ef85614834d4d246abe2d6b7ed023a0a1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "VRTX heads into its Q2 earnings release with Trikafta, Alyftrek, Casgevy and Journavx in focus as investors watch product sales and updates on ongoing pipeline studies.",
                "category": "company",
                "datetime": 1785166320,
                "headline": "Vertex Gears Up to Report Q2 Earnings: What Can Investors Expect?"
              },
              {
                "id": 141036164,
                "url": "https://finnhub.io/api/news?id=a6b6c6d4c90a0bb74ebbcd36a3334c681541ab8ecc3c1dd3fb8a84bf94227e17",
                "image": "https://cdn.benzinga.com/files/images/story/2025/11/06/aggregated_options_2.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "PFE",
                "summary": "This whale alert can help traders discover the next big trading opportunities.\nWhales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.\nTraders will",
                "category": "company",
                "datetime": 1785159309,
                "headline": "4 Health Care Stocks Whale Activity In Today’s Session"
              },
              {
                "id": 141034238,
                "url": "https://finnhub.io/api/news?id=27c83b01f75858abbfdde38bed8300b89c712a06be1adde652477ced6caab280",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2194222148/image_2194222148.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "PFE",
                "summary": "PFE’s non-COVID portfolio demonstrates resilience, with Padcev, Vyndamax, and new launches driving operational growth despite patent cliffs. Click to read.",
                "category": "company",
                "datetime": 1785153694,
                "headline": "Pfizer: Calling The Bottom - The Patent Cliff Is Real, But The Valuation Has Fallen Too Far"
              },
              {
                "id": 141031624,
                "url": "https://finnhub.io/api/news?id=9710488e858f7bc3496d73e316c57f57eef4c08c71788d8128fb3b79243512b1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Earlier this month, Pfizer announced that the FDA accepted for Priority Review a supplemental application for TALZENNA in combination with XTANDI to treat men with HRR gene‑altered metastatic castration‑sensitive prostate cancer, supported by positive Phase 3 TALAPRO‑3 results and existing approvals for later‑stage disease. This move could broaden Pfizer’s prostate cancer franchise into an earlier disease setting, potentially deepening its footprint in precision oncology and expanding the...",
                "category": "company",
                "datetime": 1785143662,
                "headline": "Did FDA’s Priority Review of TALZENNA plus XTANDI in Earlier Prostate Cancer Just Shift Pfizer's (PFE) Investment Narrative?"
              },
              {
                "id": 141034518,
                "url": "https://finnhub.io/api/news?id=ae93a4e0c783e90cf54952cde881fca7dfd6b524f165517894cc6e73681c5a02",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/27/Washington-dc--United-States--May-8-2025.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "PFE",
                "summary": "Rep. Thomas Massie questions JD Vance's silence after the Trump CDC established a $1.24 Billion Pfizer COVID-19 vaccine contract.",
                "category": "company",
                "datetime": 1785139299,
                "headline": "GOP Congressman Slams JD Vance's Silence Over CDC's $1.24 Billion Pfizer COVID Vaccine Contracts: 'Why Isn’t He Speaking Out'"
              },
              {
                "id": 141031076,
                "url": "https://finnhub.io/api/news?id=62173fbda2301693a92f3d5da56390b4ea3db8e08c290385b475eabf6e1d5a7b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "The company that used to reassure you with its sheer breadth now leads with a push to dominate oncology, and a holder who bought a diversified compounder should notice the bet has changed shape.",
                "category": "company",
                "datetime": 1785135053,
                "headline": "Johnson & Johnson Now Leads Its Pitch With An Oncology Bet"
              },
              {
                "id": 141026670,
                "url": "https://finnhub.io/api/news?id=a2dd5d7f942a1493256beacfa77ff0be06748f35ade154f9940482d373623ef7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Far from \"yield traps,\" these high-yield dividend stocks represent good value at current prices.",
                "category": "company",
                "datetime": 1785094620,
                "headline": "3 Absurdly Cheap Dividend Stocks to Buy Before August"
              },
              {
                "id": 141031075,
                "url": "https://finnhub.io/api/news?id=ca41aa6cd6ee5dd2f4fd5c0b1064c9af4a7e2344cf92122b51e1288e01279805",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "(Bloomberg) -- Investors will soon have another way to bet on the hottest stocks from Nvidia Corp. to SpaceX, without trading a single share.Most Read from BloombergDeepSeek Said to Tell Backers of Funding Pause After Viral PostsSpaceX at $100 Would Imply Zero AI Value, Morgan Stanley SaysTrump Seethes as Iran War Spirals Anew With No End in SightHouthis Claim Saudi Attack as US Ends Run of Iran StrikesRetina Chip Designed to Restore Sight to Go on Sale in EuropeCME Group Inc. will launch single",
                "category": "company",
                "datetime": 1785074400,
                "headline": "Traders Are Getting a New Tool to Wager on the Biggest US Stocks"
              },
              {
                "id": 141023533,
                "url": "https://finnhub.io/api/news?id=1973518ea4bfe34d7ac492271e7dd7de9481b497127067c660d101af4b8baf65",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1289945103/image_1289945103.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "PFE",
                "summary": "Barron’s Better Bets “Dogs” analysis: safest high-dividend stocks, fair value targets, 2027 return forecasts, and unsafe payouts flagged—read now.",
                "category": "company",
                "datetime": 1785047244,
                "headline": "Buy 4 Barron's Better Bets (Than T-Bills) Out Of 11 'Safer' July DiviDogs"
              },
              {
                "id": 141016864,
                "url": "https://finnhub.io/api/news?id=02a7054929fccd13b94135fcc42ef9eaf195056dd9ae3898a266d92a88bdf526",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Management's plain health care label has slipped out of the lead, and the business now on a separation clock is the one that finally started working.",
                "category": "company",
                "datetime": 1784989802,
                "headline": "Johnson & Johnson Is Becoming A Narrower Company Than You Bought"
              },
              {
                "id": 141016236,
                "url": "https://finnhub.io/api/news?id=45502bb052e2510ae2b04c05b236cfcf5c64a34a2efa6324cf70a893fe3ab0d4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Pfizer has a 6.8% yield at a time when the market's yield is roughly 1%: Is there something wrong?",
                "category": "company",
                "datetime": 1784982900,
                "headline": "Pfizer's Dividend Yield Looks Almost Too Good. Here's Why Management Isn't Worried."
              },
              {
                "id": 141012380,
                "url": "https://finnhub.io/api/news?id=1049f08222cb659a27f732cbe315d0815331fce9aae8adcb12d874d1f0f61c7c",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2262233592/image_2262233592.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "PFE",
                "summary": "Regeneron Pharmaceuticals, Inc. buy case: Dupixent & Libtayo fuel growth despite volatility & Eylea biosimilar risks; margins to recover. Click for an REGN update.",
                "category": "company",
                "datetime": 1784924522,
                "headline": "Regeneron: I'm Not Concerned About The Declining ROIC And Operating Margins"
              },
              {
                "id": 141007897,
                "url": "https://finnhub.io/api/news?id=0bbfb641eb9799606d45569051d0eff09b47cebdacb86a61c292ffbb1e342cfe",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "BIIB heads into Q2 results with new launches expected to offset weaker MS drug sales as investors watch Leqembi trends and the Apellis deal impact.",
                "category": "company",
                "datetime": 1784905020,
                "headline": "Biogen Q2 Earnings: Can New Drugs Counter Falling MS Sales?"
              },
              {
                "id": 141000782,
                "url": "https://finnhub.io/api/news?id=7140be4e22ad2d00ff1b03df119788c7c4ab03d25652dabb2f70f7101dbcd1f3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Could it become as successful in this niche as it was in the coronavirus vaccine market?",
                "category": "company",
                "datetime": 1784847000,
                "headline": "BioNTech's Next Act Has Nothing to Do With COVID. Here's the $500 Billion Market Some Investors Are Ignoring"
              },
              {
                "id": 140999436,
                "url": "https://finnhub.io/api/news?id=1e0e47d122f8e6d2589b24594066ddbd32eb31c22b6399fb10c2141a6f74d327",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Income seekers shouldn't give up on the stock yet.",
                "category": "company",
                "datetime": 1784841600,
                "headline": "Is Pfizer's 7% Dividend Yield Too Good to Be True? Here's the Straight Answer"
              },
              {
                "id": 140997786,
                "url": "https://finnhub.io/api/news?id=4dfdaca076fed8bec348354807b21ff775ca5e0fd371341cfb52ac26d5bb3e93",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Pfizer's Talzenna plus Xtandi combo wins FDA priority review for HRR gene-mutated metastatic castration-sensitive prostate cancer.",
                "category": "company",
                "datetime": 1784821920,
                "headline": "PFE's Talzenna sNDA Gets FDA Priority Tag in Wider Prostate Cancer Use"
              },
              {
                "id": 140993214,
                "url": "https://finnhub.io/api/news?id=e8df886607e7a4a48f8e5a5e691c2c2675b250e7843487a9c35b5aae584e5e0b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Getting kicked off the Dow Jones Industrial Average sounds like a death sentence for a stock, but a handful of booted dividend giants went on to reward patient shareholders with stunning gains and steady income streams that index investors missed out on entirely.",
                "category": "company",
                "datetime": 1784808811,
                "headline": "Verizon Was Booted From the Dow – 5 Dividend Giants Got the Same Treatment and Eventually Soared"
              },
              {
                "id": 140992563,
                "url": "https://finnhub.io/api/news?id=52dce9a0d87f6d5f5f0ed6742bffbf014e0fbdfc65ce97c0aec13b2a60a1f639",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "LONDON & SAN FRANCISCO, July 23, 2026--Verdiva Bio Limited (\"Verdiva Bio\" or the \"Company\"), a clinical-stage biotechnology company advancing the development of a portfolio of once-weekly oral therapies for obesity and obesity-related disorders, today announced that it has strengthened its leadership team with the appointment of Steve Marso, M.D. as Chief Medical Officer (CMO). Steve brings valuable clinical and regulatory experience to Verdiva following his previous roles, including as CMO at M",
                "category": "company",
                "datetime": 1784804400,
                "headline": "Verdiva Bio Appoints Cardiometabolic Leader Steve Marso as Chief Medical Officer"
              },
              {
                "id": 140991356,
                "url": "https://finnhub.io/api/news?id=4d840276aeb0d6f1dfb2fa943380324e66e059bacf6629b0c8603290a23fb52d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Big Pharma is buying its way out of the patent cliff, while Novartis AG (NYSE:NVS) is trying to out-develop it. A Record Year for Biotech Deals The scale of that buying activity appears in this year’s deal totals. Biotech M&A has hit a record pace in 2026, with deal value reaching $216 billion so far […]",
                "category": "company",
                "datetime": 1784787517,
                "headline": "Big Pharma Is Buying Growth. Novartis (NVS) Is Betting on Its Pipeline"
              },
              {
                "id": 140988040,
                "url": "https://finnhub.io/api/news?id=27d142416c421d2f8497bbc1fc5ac31113ce033af1c8d854492bfb33262d5f21",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Pfizer (PFE) is back in focus after Arbutus Biopharma and Genevant Sciences expanded their patent litigation over mRNA lipid nanoparticle technology, adding new international cases that raise legal and operational questions for the company’s COVID-19 vaccine business. See our latest analysis for Pfizer. The legal headlines around Pfizer’s mRNA vaccine coincide with a mixed price pattern, with the stock showing a 1-day share price return of 0.77% and a 7-day share price return of 2.85%, but a...",
                "category": "company",
                "datetime": 1784754525,
                "headline": "Pfizer (PFE) Faces Expanded Vaccine Lawsuits On A Fair Value Narrative That Still Sees Upside"
              },
              {
                "id": 140988041,
                "url": "https://finnhub.io/api/news?id=3e6631a5f0d64166f8a8afc754b2a4b3d90666eafa9f3178139ea1a4a1ab68ba",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "NEW YORK, July 22, 2026--Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) accepted for Priority Review a supplemental New Drug Application (sNDA) for TALZENNA® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI® (enzalutamide), an androgen receptor pathway inhibitor (ARPI), in men with homologous recombination repair (HRR) gene-altered metastatic castration-sensitive prostate cancer (mCSPC), also known as metasta",
                "category": "company",
                "datetime": 1784752200,
                "headline": "FDA Grants Priority Review for Pfizer’s TALZENNA Plus XTANDI for the Treatment of Metastatic Prostate Cancer"
              },
              {
                "id": 140984736,
                "url": "https://finnhub.io/api/news?id=2fbd4e839af7f7149a6b3e95694d3fbbb9d223f9d68fcf7f109c4a1b8a3d63c9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "ABBV's Q2 oncology revenues may edge lower as Imbruvica weakness outweighs gains from Venclexta and newer cancer therapies.",
                "category": "company",
                "datetime": 1784738280,
                "headline": "Will AbbVie's Oncology Franchise Remain Under Pressure in Q2?"
              },
              {
                "id": 140983170,
                "url": "https://finnhub.io/api/news?id=1d8293c3277709fcf4af5c0b769b69360d258065b668f508adbccf9921f21cfd",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "(Bloomberg) -- President Donald Trump’s threat of 100% tariffs against generic medicines is a major expansion of a strategy he’s been using against the pharmaceutical industry since his second term began. Most Read from BloombergTrump’s 100% Generic Drug Duty Threatens US Low-Cost SupplyApple to Launch ‘Upgrade’ Device Leasing Program With Klarna to Spur SalesTrump Extends Pardons to Companies, Echoing a 17th Century KingSpaceX Set to Unlock $116 Billion in Shares After IPO Restrictions LiftKrem",
                "category": "company",
                "datetime": 1784729414,
                "headline": "Trump Takes Another Swing at Drug Industry in Made-in-USA Push"
              },
              {
                "id": 140981764,
                "url": "https://finnhub.io/api/news?id=fe4752d3fa507f1a71bb2fbc30af30104fbf8a525645ed5a3e73ad0ec80ed866",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "A pharmaceutical giant is on an incredible run fueled by blockbuster drugs, forcing investors to ask if the price of admission already accounts for the entire victory lap.",
                "category": "company",
                "datetime": 1784726247,
                "headline": "LLY Has Momentum. The Question Is The Price"
              },
              {
                "id": 140981931,
                "url": "https://finnhub.io/api/news?id=fc999abb31ebba19c92202aac001fe1e35f42738d9cb1481ad8b366855d53dc3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "ALEXANDRIA, Va., July 22, 2026 (GLOBE NEWSWIRE) -- Pfizer’s SmartDose medications arrive pre-tagged and pre-associated for use with KitCheck, reducing manual tagging labor as part of RFID inventory management workflows Bluesight, the leader in hospital intelligence solutions, today announced a partnership with Pfizer Global Hospital & Biosimilars to integrate SmartDose RFID-enabled medications with the KitCheck inventory management platform. Through the partnership, hospitals using KitCheck can",
                "category": "company",
                "datetime": 1784721900,
                "headline": "Bluesight and Pfizer Partner to Provide Source-Tagged RFID Medications to Hospital Pharmacies"
              },
              {
                "id": 140981932,
                "url": "https://finnhub.io/api/news?id=fab036acb6e9446c3c49c28f35c20bbc11ddac44b4ef5558635037c4605b8032",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Healthcare is quietly stealing the spotlight from mega cap tech in 2026, and two S&P 500 giants are trading at valuations that suggest the market has not caught on yet.",
                "category": "company",
                "datetime": 1784721621,
                "headline": "2 Absurdly Cheap Healthcare Stocks to Buy Before July Ends"
              },
              {
                "id": 140981530,
                "url": "https://finnhub.io/api/news?id=6b6018e5672410183893a1ef8edd7db31fdb8f487a6c07dee7f72e0f18122db2",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2283703169/image_2283703169.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "PFE",
                "summary": "Novartis AG ended Q2 on a high note as oncology offset Entresto weakness; 2026 guidance reaffirmed. Read why NVS stock is upgraded to a buy.",
                "category": "company",
                "datetime": 1784712513,
                "headline": "Novartis: The Buy Thesis Is Back (Rating Upgrade)"
              },
              {
                "id": 140980672,
                "url": "https://finnhub.io/api/news?id=50b58c922e0c9aa926f433602a29e8525b738056a0af77e107d9574d4d195a28",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1828680033/image_1828680033.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "PFE",
                "summary": "Super Micro rockets higher. The clock is ticking for generic drug imports. Nike's China strategy shift.",
                "category": "company",
                "datetime": 1784703600,
                "headline": "Wall Street Breakfast Podcast: Super Micro Heats Up"
              },
              {
                "id": 140976349,
                "url": "https://finnhub.io/api/news?id=82d9525d03dbe9eedcd561c6aff3946e429bd9bd996312bd1f19747ca485afce",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Management lifted its profit outlook, and investors have more than quadrupled that bet. The question now is what they're really paying for.",
                "category": "company",
                "datetime": 1784664282,
                "headline": "Eli Lilly Stock And The Price Of Confidence"
              },
              {
                "id": 140974897,
                "url": "https://finnhub.io/api/news?id=4527046ec46f67e07022ec64ce36d30476070db35309a16067f492a6176d2f66",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "This pharma giant is grabbing headlines, but its real value for your portfolio lies in how it moves on the market's worst days.",
                "category": "company",
                "datetime": 1784658705,
                "headline": "AbbVie Stock Zigs When The Market Zags"
              },
              {
                "id": 140975002,
                "url": "https://finnhub.io/api/news?id=63e864c0230451f350a7f0a9aae510956527dd0248e85b3029dad3164796ed13",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Celcuity slides 15% despite FDA approval of Revtorpyk as investors focus on a late Q3 2026 launch that delays commercial sales and near-term revenues.",
                "category": "company",
                "datetime": 1784654820,
                "headline": "Why CELC Stock Declined 15% in a Week Despite a Major FDA Win"
              },
              {
                "id": 140971736,
                "url": "https://finnhub.io/api/news?id=16219f52d57ac065bea3a077071416cb007d93f090f3a0f592b90d2a999d4612",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Pfizer's non-oncology portfolio faced mixed Q2 trends. Eliquis and Vyndaqel sales may have risen while COVID products will have declined.",
                "category": "company",
                "datetime": 1784642700,
                "headline": "What to Watch in Pfizer's Non-Oncology Portfolio This Earnings Season"
              },
              {
                "id": 140966269,
                "url": "https://finnhub.io/api/news?id=8779c3a46969bd7ab96f5cb6189949029d9e6633680619e3ed64bb91d8f6de71",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "In the latest trading session, Pfizer (PFE) closed at $24.75, marking a -1.2% move from the previous day.",
                "category": "company",
                "datetime": 1784583907,
                "headline": "Pfizer (PFE) Falls More Steeply Than Broader Market: What Investors Need to Know"
              },
              {
                "id": 140963403,
                "url": "https://finnhub.io/api/news?id=f4884d142c8fe4723c200af3df0c71c73b1c873e2c314a7447d92ad950c86ede",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "The healthcare giant's pharma division is booming, but analysts on its latest call wanted to know if that's enough to cover for a sudden slowdown in MedTech.",
                "category": "company",
                "datetime": 1784573756,
                "headline": "Reading Between The Lines Of JNJ Stock's Latest Call"
              },
              {
                "id": 140960743,
                "url": "https://finnhub.io/api/news?id=247ca722714d55543123d5669b3823aef98ee2173918597d271bf92d2cda4526",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Arbutus Biopharma and Genevant Sciences have filed multiple patent infringement lawsuits against Pfizer and BioNTech over their mRNA-LNP COVID-19 vaccines. The new cases extend beyond the existing U.S. litigation into several international jurisdictions. The lawsuits seek monetary damages and potential injunctions on vaccine products, raising legal and operational risks for Pfizer. Pfizer, listed as NYSE:PFE, is facing an expanded legal challenge as Arbutus Biopharma and Genevant Sciences...",
                "category": "company",
                "datetime": 1784560181,
                "headline": "Pfizer (PFE) Faces New International Patent Lawsuits Over Covid 19 Vaccine"
              },
              {
                "id": 140959619,
                "url": "https://finnhub.io/api/news?id=2592fde1e6ce1f2466206ba82a54f43d47a6eef8bf6b50d215c693a68291606d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Stocks in the $10-50 range offer a sweet spot between affordability and stability as they’re typically more established than penny stocks. But their headline prices don’t guarantee quality, and investors should exercise caution as some have shaky business models.",
                "category": "company",
                "datetime": 1784554053,
                "headline": "1 Stock Under $50 to Target This Week and 2 We Question"
              },
              {
                "id": 140972332,
                "url": "https://finnhub.io/api/news?id=9ca45909deb2d748dc14e482974297e36cd821db9832492a9d912f9bdaecc884",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/20/Shanghai--China--Nov--6--2022-Pfizer-Sig.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "PFE",
                "summary": "A Premarin shortage in India leaves menopausal patients facing limited treatment options as Pfizer halts cream distribution.",
                "category": "company",
                "datetime": 1784553507,
                "headline": "Pfizer Suspends Popular Menopause Cream in India"
              },
              {
                "id": 140960744,
                "url": "https://finnhub.io/api/news?id=d55f08b990218028e8864dc98dea34f4730f1013da16555883e2ca0faf88ed15",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Pfizer (PFE) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",
                "category": "company",
                "datetime": 1784552403,
                "headline": "Is Trending Stock Pfizer Inc. (PFE) a Buy Now?"
              },
              {
                "id": 140959510,
                "url": "https://finnhub.io/api/news?id=a9c2ac51c5f6093a7eef3814a52242e894c9058def09703ffad12d8ef3fb6476",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "For many cancers now, the standard treatment is chemotherapy plus an immunotherapy such as  Merck  Keytruda, the best-selling drug in the world.  Many think it will pair two innovations: precisely-targeted chemo drugs known as antibody-drug conjugates, or ADCs, and augmented immunotherapies in the form of bispecific antibodies.  Bispecific antibodies are being tested by  Bristol Myers Squibb  (with its partner  BioNTech  ),  AstraZeneca  and the biotech firm  Summit Therapeutics  ADCs have already rung up big sales for Astra,  Pfizer Gilead Sciences  and  Roche Holding  but Merck has a strong contender in development.",
                "category": "company",
                "datetime": 1784549820,
                "headline": "Merck’s Keytruda Faces a Patent Cliff. These New Cancer Drugs Could Take Over."
              },
              {
                "id": 140961123,
                "url": "https://finnhub.io/api/news?id=0617690bb008a2dddf3672e42d00cf7cdf55f63a846c07b0ff07f8f12209951c",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2208146516/image_2208146516.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "PFE",
                "summary": "Eikon Therapeutics focuses on the development of solid tumor therapies. Read more on recent trials for this California-based biotech.",
                "category": "company",
                "datetime": 1784549100,
                "headline": "Eikon Therapeutics: Behind The Rough Debut"
              },
              {
                "id": 140957623,
                "url": "https://finnhub.io/api/news?id=92ea0d89769ccd4230fa5db8bca470f773332f330639ae313830bf85e77936eb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "It is definitely a strong contender.",
                "category": "company",
                "datetime": 1784532900,
                "headline": "Could Pfizer Ultimately Be the Biggest Winner in the $100 Billion Weight-Loss Market?"
              },
              {
                "id": 140951120,
                "url": "https://finnhub.io/api/news?id=e1476b568cc054e9bc20cdef41e29e92e4be1337822503ab7d3d7e9678907492",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Pfizer is a highly respected drug company facing normal industry headwinds.",
                "category": "company",
                "datetime": 1784460900,
                "headline": "Looking for Cheap Income Stocks? Why Pfizer Belongs on Your Shortlist Right Now"
              },
              {
                "id": 140943120,
                "url": "https://finnhub.io/api/news?id=d4cfff3bdae9f1bd74e2bc2b3b7907478903d3d1fb7f88ed9c4f956de0a0d6ae",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Pfizer's dividend yield is 7% for a very good reason: investors are worried about the risk of a dividend cut.",
                "category": "company",
                "datetime": 1784381700,
                "headline": "Pfizer Paid Out $14.6 Billion in Dividends Over the Last 18 Months. Can It Keep This Up Through the Patent Cliff?"
              },
              {
                "id": 140944469,
                "url": "https://finnhub.io/api/news?id=b5473b5e218fa09a16b46b6e5c24f774f88167fed580755ba05200e7f3171e3c",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2170932409/image_2170932409.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "PFE",
                "summary": "Discover dividend stocks and REITs to hedge AI bubble risk, geopolitics, and inflation. Click for this survey of great income choices and my ultimate pick.",
                "category": "company",
                "datetime": 1784379799,
                "headline": "AI Bubble Risks Make Dividend Stocks Attractive Again"
              },
              {
                "id": 140943503,
                "url": "https://finnhub.io/api/news?id=856676616f1aa74556899577c7f985b134cf726bf0bd06eec0612fd7745179ba",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "PFE",
                "summary": "Preview next week’s key market events—earnings (GOOG, TSLA, INTC), PMI/jobs data, dividends, volatility, and sector risks.",
                "category": "company",
                "datetime": 1784372400,
                "headline": "Google, Tesla, Intel To Headline Earnings Next Week"
              },
              {
                "id": 140940379,
                "url": "https://finnhub.io/api/news?id=313b6b852fad87101bd818b159b0149e5266b64044b5717f092ff2ac4d12ad63",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1072593728/image_1072593728.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "PFE",
                "summary": "A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Read here for an analysis.",
                "category": "company",
                "datetime": 1784329960,
                "headline": "Dividend Champion, Contender, And Challenger Highlights: Week Of July 19"
              },
              {
                "id": 140939161,
                "url": "https://finnhub.io/api/news?id=f57b9ce7b4402974f3ad4605a0ce95da73880c2e007cc7fb1d99cb560f207f71",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "The drugmaker looks expensive today, but the real story is what you are actually paying for the earnings of tomorrow.",
                "category": "company",
                "datetime": 1784325063,
                "headline": "The Real Question Buried Inside Merck Stock's Premium Price"
              },
              {
                "id": 140934902,
                "url": "https://finnhub.io/api/news?id=de08541083e863140f830218ccba6086caa27011c1ec38c5dc4b730cd52934a0",
                "image": "https://www.chartmill.com/images/uploads/CM_Most_Active_Stocks_Small_free_fec0650b7f.webp",
                "source": "ChartMill",
                "related": "PFE",
                "summary": "Curious about the most active S&P500 stocks in today's session? Join us as we explore the US markets on Friday and uncover the stocks that are leading the way in terms of trading volume and market attention.",
                "category": "company",
                "datetime": 1784311502,
                "headline": "Curious about the most active S&P500 stocks in today's session?"
              },
              {
                "id": 140934498,
                "url": "https://finnhub.io/api/news?id=d5e325853357032801312770e7b99a6265e4d99d76ac402f46ae2fcc455526af",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Gilead stock is closely tied to its HIV treatments. But with Biktarvy's patent expirations looming, can the giant survive?",
                "category": "company",
                "datetime": 1784307294,
                "headline": "Gilead Leads The Battle Vs. HIV. But Rivals Are On The Move."
              },
              {
                "id": 140936816,
                "url": "https://finnhub.io/api/news?id=dfc213e3151303a62bf12cf3db7126a5be2b9acbf3f914b66182e6e66db10abb",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/17/Us-Senator-Tommy-Tuberville-Speaks-On-Th.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "PFE",
                "summary": "Sen. Tommy Tuberville is cashing out of stocks in 2026. Here's the list.",
                "category": "company",
                "datetime": 1784303289,
                "headline": "Senator Who Opposes Ban on Congress Trading Discloses First Trades of 2026: Here’s What He’s Selling"
              },
              {
                "id": 140931453,
                "url": "https://finnhub.io/api/news?id=4cd13d9255fd7a1f4cec980f8e5bdb9ee6c2648493b15665ee509ea0505422ab",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "When a regular paycheck disappears in retirement, the stakes of every investment decision skyrocket. These five high-yield stocks earning 6% or more are winning over Boomers who refuse to let rising prices eat their savings alive.",
                "category": "company",
                "datetime": 1784291730,
                "headline": "Boomers Swear by These High-Yield 5% and More Kings They Can Buy and Hold Forever"
              },
              {
                "id": 140933093,
                "url": "https://finnhub.io/api/news?id=a4cd3c507c482d8f1957c9ad2e3b0bb58a656a4187d89ec4a698b1241eeb7f45",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "The new lawsuits add to a web of legal disputes over technology involved in COVID vaccines. Elsewhere, a prolific AI biotech inked another deal and Insmed strengthened support for a closely watched blood pressure drug.",
                "category": "company",
                "datetime": 1784282845,
                "headline": "Arbutus, Sanofi escalate mRNA patent fights; InnoCare’s TYK2 contender advances"
              },
              {
                "id": 140929072,
                "url": "https://finnhub.io/api/news?id=405a05fc41aab22c382255930ba97d658555a30994d96cac9cd5312c989a4307",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "All three can be bought on the dip.",
                "category": "company",
                "datetime": 1784265600,
                "headline": "3 High-Yield Dividend Stocks to Buy and Hold"
              },
              {
                "id": 140924528,
                "url": "https://finnhub.io/api/news?id=f1e1715ec5ef89b9077a66a3ae648149c25e397177105374f1afe0fa2ef540fb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "On July 8, Arbutus received around $178 million from Moderna as part of a patent litigation settlement, the company said.",
                "category": "company",
                "datetime": 1784227263,
                "headline": "ABUS Stock On Track For Best Day In About Two Months — What’s The Moderna Connection?"
              },
              {
                "id": 140923055,
                "url": "https://finnhub.io/api/news?id=687d76e8755cf2f32604a790184741ca6968641065313a652129ba98ee9e72f8",
                "image": "https://www.chartmill.com/images/uploads/CM_Most_Active_Stocks_Small_free_fec0650b7f.webp",
                "source": "ChartMill",
                "related": "PFE",
                "summary": "Explore the S&P500 index on Thursday and find out which stocks are the most active in today's session. Stay updated with the stocks that are capturing market interest and driving market movements.",
                "category": "company",
                "datetime": 1784225101,
                "headline": "Explore the S&P500 index on Thursday and find out which stocks are the most active in today's session."
              },
              {
                "id": 140922760,
                "url": "https://finnhub.io/api/news?id=1a3df35e3ff26d502cbd77c9a1fe4acac03128a5eb0ebe0dce646e0ce7542141",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "After a tough stretch for shareholders over the last five years, with Pfizer stock down about 22% over that window, the current valuation sits in a middle ground where the broader pricing checks look mixed rather than clearly cheap or clearly expensive. Pfizer has delivered a decline of roughly 22% over five years, which frames any current pricing as a potential reset rather than the tail end of a long rally. Recent approvals and oncology progress can support expectations for future cash...",
                "category": "company",
                "datetime": 1784221964,
                "headline": "Pfizer (PFE) Stock Looks Fairly Priced With Pipeline Risks In View"
              },
              {
                "id": 140920959,
                "url": "https://finnhub.io/api/news?id=5ca65886125060506cbb858303589dfe9feb9b4c15f873a6449871aa096ae0c2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "PFE trades below key moving averages as investors weigh fading COVID sales against pipeline growth, acquisitions and a low valuation with a high dividend.",
                "category": "company",
                "datetime": 1784213040,
                "headline": "Pfizer Stock Below 50-Day and 200-Day SMA: Buy the Dip or Exit Now?"
              },
              {
                "id": 140923089,
                "url": "https://finnhub.io/api/news?id=57a2cfd487ec6d31a565a803e84295626f4737a5e11a4f22c1670fa1c36ac530",
                "image": "",
                "source": "Benzinga",
                "related": "PFE",
                "summary": "- Reuters Exclusive ",
                "category": "company",
                "datetime": 1784208946,
                "headline": "'Pfizer Temporarily Discontinues Premarin Vaginal Cream In India, Citing Supply Challenges; Pfizer Says Exploring Options To Resume Supply Of Premarin Vaginal Cream In India As Soon As Possible'"
              },
              {
                "id": 140919686,
                "url": "https://finnhub.io/api/news?id=73e8666060b1415c53da17946bd06f234dc80c8765b33ed82a66e02cf0745fc2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "While the market focuses on a single class of blockbuster drugs, a different story is unfolding inside the company. Lilly’s immunology, oncology, and neuroscience medicines are quietly compounding at a blistering pace. These other therapeutic areas collectively grew by 160% last quarter, a rate that suggests a much broader growth engine is taking shape.",
                "category": "company",
                "datetime": 1784207994,
                "headline": "What Could Push LLY Stock Higher From Here?"
              },
              {
                "id": 140919685,
                "url": "https://finnhub.io/api/news?id=8aaaa1ac492f93cd7e2c8a593e3ee9b65133645f1fcce9caf8568dc8cb52f96d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "While many investors focus on a slowdown in one business segment, they may be overlooking the remarkable growth occurring in another.",
                "category": "company",
                "datetime": 1784207994,
                "headline": "The Real Engine Behind Johnson & Johnson Stock's Next Climb"
              },
              {
                "id": 140919720,
                "url": "https://finnhub.io/api/news?id=9d2f9b3f8a8731e901d1e5ad81cf41b276753ec46ea230c1fd3ca2fe7db06730",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "The pharma division is firing on all cylinders, but a sudden crack in the MedTech business has the market worried about the company's new two-part growth plan.",
                "category": "company",
                "datetime": 1784205864,
                "headline": "Why Is The Market Punishing JNJ Stock?"
              },
              {
                "id": 140918921,
                "url": "https://finnhub.io/api/news?id=a55e4c8b6ce0a21c79c97c228a610dad6931a94cff4a46dfd5fe6ccc4b01ebfb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Arbutus and its exclusive licensee, Genevant, filed three international lawsuits seeking to enforce patents protecting their innovative lipid nanoparticle (“LNP”) technology against Pfizer and BioNTech Received approximately $178M from Moderna as Arbutus’ share of the noncontingent payment under the March 2026 Settlement Agreement resolving litigation over Moderna’s infringement of Arbutus’ LNP patents Anticipates receipt of a dividend from Genevant in Q3 2026 Expects to return up to approximate",
                "category": "company",
                "datetime": 1784201400,
                "headline": "Arbutus Initiates International Patent Infringement Enforcement Actions Against Pfizer and BioNTech, Receives First Payment From Moderna Settlement Agreement and Announces Intent to Return Capital to Shareholders"
              },
              {
                "id": 140920447,
                "url": "https://finnhub.io/api/news?id=4d55abc6b92de42bd2905a7120c70b519975b77b460bae9c9dcdc27c17b40f15",
                "image": "",
                "source": "Benzinga",
                "related": "PFE",
                "summary": "Arbutus and its exclusive licensee, Genevant, filed three international lawsuits seeking to enforce patents protecting their innovative lipid nanoparticle ("LNP") technology against Pfizer and BioNTech Received",
                "category": "company",
                "datetime": 1784187572,
                "headline": "Arbutus Biopharma Announces Filing Of Three International Lawsuits Seeking To Enforce Patents Protecting LNP Technology Against Pfizer, BioNTech And Certain Of Their Affiliates"
              },
              {
                "id": 140917050,
                "url": "https://finnhub.io/api/news?id=4a9b30659a8b6f77879f9b05bb5934e6989ece734487e635c7de4deeccca076a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "MetroLoft and Quantum Pacific bought 1 Whitehall St. for $104.5M to convert the FiDi office tower into housing.",
                "category": "company",
                "datetime": 1784174383,
                "headline": "MetroLoft Leads $104M Office-to-Residential Bet in FiDi"
              },
              {
                "id": 140911186,
                "url": "https://finnhub.io/api/news?id=d2612052d9f84c92d994a744608379e467802d35adcdb495958f835110241182",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Johnson and Johnson has quietly become one of the best-performing mega-caps of the past year, but with a fresh pullback and a pipeline firing on multiple cylinders, the bigger question is whether the next leg higher finally breaks through to record territory.",
                "category": "company",
                "datetime": 1784136544,
                "headline": "Prediction: This Dividend King Could End The Year With a New All-Time High Stock Price"
              },
              {
                "id": 140911297,
                "url": "https://finnhub.io/api/news?id=787e4c2e5b8b34dbaa7ba190f36e70608d9c07c20239be6b5eb232e1e3172fd9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Johnson and Johnson just raised guidance while absorbing nine-figure litigation charges, and the stock is still near levels that have historically rewarded patient buyers. Whether the talc courtroom drama is drowning out a rare compounding opportunity depends on what the numbers actually say.",
                "category": "company",
                "datetime": 1784132843,
                "headline": "Stock Market Is Giving A Pristine Entry Point Into This 64-Year Dividend King"
              },
              {
                "id": 140909789,
                "url": "https://finnhub.io/api/news?id=9386bda867bc862800f23229e243a124b0981b9d2c48774b2d852bbf0295d183",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Pfizer Inc. (NYSE:PFE) is one of the 8 Worst Blue Chip Stocks to Buy Now. On July 10, 2026, Pfizer Inc. (NYSE:PFE) and Astellas Pharma (ALPMY) announced that the U.S. Food and Drug Administration approved PADCEV, a Nectin-4 directed antibody-drug conjugate, plus the PD-1 inhibitor Keytruda or Keytruda QLEX as neoadjuvant and adjuvant treatment for […]",
                "category": "company",
                "datetime": 1784125485,
                "headline": "Pfizer (PFE) Announces FDA Approval of PADCEV plus Keytruda in MIBC"
              },
              {
                "id": 140909790,
                "url": "https://finnhub.io/api/news?id=af15234f4b9ec920035a95ad689421bcb570b7a755264fea874eddfb5e33e5a6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "OLDWICK, N.J., July 15, 2026--AM Best has affirmed the Financial Strength Rating of A (Excellent) and the Long-Term Issuer Credit Rating of \"a+\" (Excellent) of Blue Whale Re Ltd. (Blue Whale) (Burlington, VT). The outlook of these Credit Ratings (ratings) is stable.",
                "category": "company",
                "datetime": 1784124240,
                "headline": "AM Best Affirms Credit Ratings of Blue Whale Re Ltd."
              },
              {
                "id": 140908120,
                "url": "https://finnhub.io/api/news?id=b8c6e3ec8611b248e30d1d53e25eef6984f5dfa5a8b1b6aed9bb11253f63d462",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Both Pfizer and Gilead Sciences just flashed the same ominous technical warning while trading below analyst fair value, but the reasons behind each selloff tell very different stories about which one actually deserves a second look.",
                "category": "company",
                "datetime": 1784121009,
                "headline": "Is the Bearishness Around Pfizer and Gilead Sciences a Contrarian Opportunity?"
              },
              {
                "id": 140910531,
                "url": "https://finnhub.io/api/news?id=57000288ae8e34864fe003c9dc01032ef3345e614ac1f58d27e5e9465af2590c",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1365641802/image_1365641802.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "PFE",
                "summary": "AstraZeneca PLC Q2 2026 preview: revenue growth, Enhertu sales surge and EU approval, plus risk/reward after Wainua trial setback. Click for this AZN stock update.",
                "category": "company",
                "datetime": 1784120082,
                "headline": "AstraZeneca's Oncology Engine Keeps Running Despite Wainua Setback"
              },
              {
                "id": 140911427,
                "url": "https://finnhub.io/api/news?id=3864310df763c64d5566d2d259f9910e928215f771e86fe4a0f597247a5e1c5c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Still, shares fell by nearly 20% after the company revealed a delay in the coming launch of Revtorpyk. Details in the drug’s prescribing information surprised some analysts, too.",
                "category": "company",
                "datetime": 1784117880,
                "headline": "Celcuity gains FDA approval for closely-watched breast cancer drug"
              },
              {
                "id": 140904303,
                "url": "https://finnhub.io/api/news?id=0d35bf0410c05cd8dcd88eb4f28daa527ac884d0fec18dd5ad396e2e3e48d508",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Pfizer, trading as NYSE:PFE, received FDA approval for a platinum-free Padcev-Keytruda regimen in muscle-invasive bladder cancer. The regimen is approved as both neoadjuvant and adjuvant therapy for adult patients, regardless of cisplatin eligibility. This decision expands use of the combination across a broader bladder cancer population and introduces a new treatment option. For investors watching Pfizer at a share price of $24.25, this approval adds a fresh development to the oncology...",
                "category": "company",
                "datetime": 1784067344,
                "headline": "Pfizer (PFE) Wins FDA Approval For First Platinum Free Bladder Cancer Regimen"
              },
              {
                "id": 140903043,
                "url": "https://finnhub.io/api/news?id=74b513199a33bea6cd71108e09711b0ef0769e4e54ff9fdb035e060ae1ee3375",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Gedatolisib, in-licensed from Pfizer in 2021, is Celcuity’s sole late-stage asset.",
                "category": "company",
                "datetime": 1784064285,
                "headline": "CELC Stock Clocks Best Day In About 2 Months On First FDA Approval For Cancer Drug"
              },
              {
                "id": 140901360,
                "url": "https://finnhub.io/api/news?id=3e6e42c781120e15aab58bad7e449e276fadbd2b206c04f72dc6d3cb81f730d6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "These stocks offer a good mix of dividends, growth, and long-term stability.",
                "category": "company",
                "datetime": 1784053200,
                "headline": "3 of the Best Stocks to Buy for Less Than $100 Right Now"
              },
              {
                "id": 140901439,
                "url": "https://finnhub.io/api/news?id=64cd56311f93e5171b803be30ef3da8f9f5b6d1c652a2a55be30635d893b79a0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "In the world of big pharma, one company is both the star performer and the most expensive name on the marquee, forcing investors to ask if the price of admission is simply too high.",
                "category": "company",
                "datetime": 1784051674,
                "headline": "What Lilly's Peer-Beating Numbers Cost You"
              },
              {
                "id": 140899749,
                "url": "https://finnhub.io/api/news?id=84094e3225d70c38db6c6d50a9e1c231ea6494cc942138536531dc77bf34a499",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Johnson and Johnson just raised its full-year outlook toward a historic $100 billion revenue target, yet the stock still trades well below where our model says it should be. The real question is whether the pipeline can outrun the headwinds closing in fast.",
                "category": "company",
                "datetime": 1784046620,
                "headline": "This Healthcare Giant Still Checks Every Box for Long-Term Investors"
              },
              {
                "id": 140898221,
                "url": "https://finnhub.io/api/news?id=a5052686d64fade991382304b35ce4aaa4ced4362c7202aef97d0f976c633d82",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Pfizer (NYSE: PFE) and Amgen (NASDAQ: AMGN) both reported Q1 2026 results this quarter, and the numbers reveal two very different bets on the future of oncology. Pfizer is monetizing its Seagen deal today. Amgen is defending a biosimilar cliff while spending to rebuild growth from scratch. Padcev Carries Pfizer. Biosimilars Bite Amgen. Pfizer’s oncology ... Pfizer Vs. Amgen: Bet That Pfizer’s Seagen Integration Leads to Long-Term Oncology Alpha Over Amgen",
                "category": "company",
                "datetime": 1784044263,
                "headline": "Pfizer Vs. Amgen: Bet That Pfizer’s Seagen Integration Leads to Long-Term Oncology Alpha Over Amgen"
              },
              {
                "id": 140900776,
                "url": "https://finnhub.io/api/news?id=472ffc9e1c34527f50c19adb2c3e53aab6255066151051c2bc57b056856451e8",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2237287346/image_2237287346.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "PFE",
                "summary": "SELLAS Life Sciences is at the center of a debate over its event-driven Phase 3 REGAL trial for GPS in AML CR2 patients. Read more on SLS stock here.",
                "category": "company",
                "datetime": 1784041616,
                "headline": "SELLAS Life Sciences: Strong Buy-Imminent Catalyst, Dual-Platform Pipeline, And A Market That Hasn't Caught Up"
              },
              {
                "id": 140897970,
                "url": "https://finnhub.io/api/news?id=2a91f1eab4ba0bfb85a889d1f8bb99e4327f89e0200e8ebe1294bb240752215c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "The pharma giant's yield of around 7.1% is more than six times the S&P 500 average.",
                "category": "company",
                "datetime": 1784040279,
                "headline": "Pfizer Has the Highest-Yielding Dividend in the S&P 500. Should Investors Be Worried?"
              },
              {
                "id": 140898076,
                "url": "https://finnhub.io/api/news?id=f40aa289b2dde6583d36a61262e45aaeea6e34024e49b68b4911c34191600fe3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "PFE's oncology business is in focus ahead of Q2 results as growth from key cancer drugs, biosimilars and pipeline updates may offset declines in older therapies.",
                "category": "company",
                "datetime": 1784039400,
                "headline": "Here's How Pfizer's Oncology Growth Story Looks Ahead of Q2 Results"
              },
              {
                "id": 140903044,
                "url": "https://finnhub.io/api/news?id=0bae6503542527b09743a8331251976e36036996f1e1d47cde9c8d4433c9ce12",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Pfizer is set to announce its second-quarter earnings next month, and Wall Street expects a double-digit decline in its profit.",
                "category": "company",
                "datetime": 1784037752,
                "headline": "Here's What to Expect From Pfizer's Next Earnings Report"
              },
              {
                "id": 140898155,
                "url": "https://finnhub.io/api/news?id=6d4a33b47289f081e1decf603f5fe621103805f6f365d34500b2ac909e8a981c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "BMY's FDA filing for mezigdomide in relapsed or refractory multiple myeloma marks another step in advancing its protein degrader pipeline.",
                "category": "company",
                "datetime": 1784037180,
                "headline": "Can BMY's CELMoD Program Advancements Strengthen Its Oncology Portfolio?"
              },
              {
                "id": 140896832,
                "url": "https://finnhub.io/api/news?id=cd7d8f48709f03cfb02a2c4fe33cae2ce945561754784b3a831991e3b9c5278f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "SAN FRANCISCO, July 14, 2026--Chai Discovery, the company engineering AI models to discover new molecules, today announced a $400M Series C fundraise to further accelerate progress.",
                "category": "company",
                "datetime": 1784034000,
                "headline": "Chai Discovery Announces $400M Series C to Advance AI-Driven Molecular Design"
              },
              {
                "id": 140895235,
                "url": "https://finnhub.io/api/news?id=8d9777b0e7b101d7c72de663e31a949ba16e667fd31714d568fa328129eab30d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Drug pricing matters, but pipelines matter even more.",
                "category": "company",
                "datetime": 1784020800,
                "headline": "Donald Trump's Drug-Pricing Deals Are Reshaping Big Pharma -- Here's What That Means for Pfizer, AbbVie, and Bristol Myers Squibb"
              },
              {
                "id": 140892604,
                "url": "https://finnhub.io/api/news?id=70b4ffa6a7e0d2467fcad41f73f76289415dae7c7350e32e685fa160727d949d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "In the latest trading session, Pfizer (PFE) closed at $24.48, marking a +1.28% move from the previous day.",
                "category": "company",
                "datetime": 1783979104,
                "headline": "Pfizer (PFE) Advances While Market Declines: Some Information for Investors"
              },
              {
                "id": 140891229,
                "url": "https://finnhub.io/api/news?id=0a023d46a31322023b8459e9579bf4e88d08889b900df99a7955bcccc5f83e6b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Abbott is down nearly 23% this year while Pfizer dangles a 7% yield, and both just beat Q1 estimates. One of these discounts is a genuine buying opportunity and the other is a slow-moving trap waiting to spring.",
                "category": "company",
                "datetime": 1783975629,
                "headline": "Abbott Labs Vs. Pfizer: Which Discounted Healthcare Titan Screens as the Bigger Value Trap?"
              },
              {
                "id": 140888922,
                "url": "https://finnhub.io/api/news?id=2688322ca92f5d3c1483ed79195c577694d4737e96ae3a9fb8e5d3ea5d3e792a",
                "image": "https://www.chartmill.com/images/uploads/CM_Most_Active_Stocks_Small_free_fec0650b7f.webp",
                "source": "ChartMill",
                "related": "PFE",
                "summary": "Stay informed about the most active S&P500 stocks in today's session as we take a closer look at what's happening on the US markets on Monday. Discover the stocks that are generating the highest trading volume and driving market activity.",
                "category": "company",
                "datetime": 1783965900,
                "headline": "Stay informed about the most active stocks in the S&P500 index on Monday's session."
              },
              {
                "id": 140890874,
                "url": "https://finnhub.io/api/news?id=aeb09051fefdeb721b42719b840455732c5c7611df00d7c438365a90396a98a1",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2232628653/image_2232628653.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "PFE",
                "summary": "The Undercovered Dozen series spotlights 12 lesser-covered stocks featured on Seeking Alpha between July 3 and July 9. Read the full analysis here.",
                "category": "company",
                "datetime": 1783962834,
                "headline": "Undercovered Dozen: SK Hynix, Reddit, Austal, Netlist, And More"
              },
              {
                "id": 140899912,
                "url": "https://finnhub.io/api/news?id=f119677899fbdd7f63b09022521d1d719f9201abde7ec4ff3e3252540d96d8a8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Wainua missed its Phase 3 endpoint, hitting Ionis Pharmaceuticals hard while AstraZeneca absorbed the blow easily, boosting rivals BridgeBio, Pfizer and Alnylam Pharmaceuticals.",
                "category": "company",
                "datetime": 1783959900,
                "headline": "The Phase 3 Failure That Sent Biotech Winners and Losers in Opposite Directions"
              },
              {
                "id": 140887166,
                "url": "https://finnhub.io/api/news?id=bfd84f7f61e8d798579c452c81fa0dc1d6689e69aea2fca608e0e14e8393f127",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The key risk, however, is that these stocks are usually cheap for a reason — five cents for a piece of fruit may seem like a great deal until you find out it’s rotten.",
                "category": "company",
                "datetime": 1783958319,
                "headline": "2 Value Stocks Worth Your Attention and 1 Facing Headwinds"
              },
              {
                "id": 140888430,
                "url": "https://finnhub.io/api/news?id=1878947d921411a7abc93a44daf05abd7d3b58271e42b8bb5bee329f2cdc7de1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Merck's Keytruda in combination with Pfizer's Padcev wins FDA nod for expanded use in muscle-invasive bladder cancer, regardless of cisplatin eligibility.",
                "category": "company",
                "datetime": 1783955280,
                "headline": "FDA Expands MRK & PFE's Keytruda-Padcev Combo Use in Bladder Cancer"
              },
              {
                "id": 140888226,
                "url": "https://finnhub.io/api/news?id=2fc7e2002ab8e39cabb3974c06cad1fde6ceec9d2584a7770aa6b20f081d01e9",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2184220601/image_2184220601.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "PFE",
                "summary": "Build a resilient dividend income portfolio with quality stocks & ETFs: 3.75% yield, low payout ratios, low beta, and defensive sector focus. Here's what investors need to consider.",
                "category": "company",
                "datetime": 1783950349,
                "headline": "How To Build A $50,000 Dividend Portfolio In Today's Market"
              },
              {
                "id": 140885957,
                "url": "https://finnhub.io/api/news?id=c3654f647a3a47105890017a1058d688704c7d5e8383e61c6ed4d24e55ec464f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "The company's pipeline is more advanced than ever, but its history shows a pattern of deep, prolonged drops when the market turns.",
                "category": "company",
                "datetime": 1783948328,
                "headline": "What It Means To Hold Moderna Stock In A Crash"
              },
              {
                "id": 140885768,
                "url": "https://finnhub.io/api/news?id=beb87ad176efb9fdff630913987b4267d509627241251c66ccf0cea69cf5af22",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "At $1,189, Eli Lilly (LLY) looks set up for roughly 76% of upside over the next three years under a conservative scenario. That is a move large enough to justify digging into where it comes from. Revenue compounding does the work, but the multiple takes a meaningful cut along the way. Here is the operational reality the math is built on.",
                "category": "company",
                "datetime": 1783948326,
                "headline": "How Does LLY Stock Reach $2,100?"
              },
              {
                "id": 140885670,
                "url": "https://finnhub.io/api/news?id=550549e70d592f1616b71600c3535938a693ddd64a3aa9d85eaf5bda54146da8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Johnson & Johnson (NYSE:JNJ) is the easiest healthcare name to evaluate on the board heading into its July 15 earnings release, and the setup leaves little to debate. The stock has already told you what it thinks of the fundamentals, rising nearly 25% year to date and nearly 66% over the past year. Yet the ... The Real Case for Buying Johnson & Johnson (JNJ) Before July 15",
                "category": "company",
                "datetime": 1783945817,
                "headline": "The Real Case for Buying Johnson & Johnson (JNJ) Before July 15"
              },
              {
                "id": 140887030,
                "url": "https://finnhub.io/api/news?id=ebd3f3e20b919caca3b275cc6ed107af02a39aed3c67612fd238370692c6aeae",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Agenus is financially abandoning an ongoing study in late-line colorectal cancer. Elsewhere, an ebola vaccine began human testing and an important Bristol Myers medicine got an FDA decision date.",
                "category": "company",
                "datetime": 1783943162,
                "headline": "Agenus surges on study pivot; Apnimed lines up an IPO"
              },
              {
                "id": 140887931,
                "url": "https://finnhub.io/api/news?id=e7bc2ada588cf2adac84f1c0501fa0221bd7ce5aaec251bb11ce57714a088ce5",
                "image": "https://image.cnbcfm.com/api/v1/image/108331043-1783365848624-gettyimages-2280068333-sc1_1154_pvccmh9y.jpeg?v=1783365884&w=1920&h=1080",
                "source": "CNBC",
                "related": "PFE",
                "summary": "Economy is one of the most important categories in CNBC’s annual America’s Top States for Business rankings. Several states stand out for economic strength.",
                "category": "company",
                "datetime": 1783936801,
                "headline": "The 10 best state economies in America in 2026"
              },
              {
                "id": 140890438,
                "url": "https://finnhub.io/api/news?id=ce59f8f85d8c4564d4ea741eeb69d819f6f37d456c599ae41c1c0e2c9e16146b",
                "image": "",
                "source": "Benzinga",
                "related": "PFE",
                "summary": "BMO Capital  analyst Evan David Seigerman   maintains Pfizer (NYSE:PFE) with a Outperform and lowers the price target from $34 to $30.",
                "category": "company",
                "datetime": 1783933265,
                "headline": "BMO Capital Maintains Outperform on Pfizer, Lowers Price Target to $30"
              },
              {
                "id": 140890439,
                "url": "https://finnhub.io/api/news?id=868eed96da6c70484c357e6e7e2229727712165228fd15adf20c8a9479f0e517",
                "image": "",
                "source": "Benzinga",
                "related": "PFE",
                "summary": "Guggenheim  analyst Vamil Divan   maintains Pfizer (NYSE:PFE) with a Buy and lowers the price target from $36 to $35.",
                "category": "company",
                "datetime": 1783932440,
                "headline": "Guggenheim Maintains Buy on Pfizer, Lowers Price Target to $35"
              },
              {
                "id": 140875649,
                "url": "https://finnhub.io/api/news?id=97e3f3d38ff4e7a208c0055384f0270997697dc002000a4d9dd4fe343e0b943e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "These high-yield stocks have long track records of dividend consistency and growth.",
                "category": "company",
                "datetime": 1783842300,
                "headline": "3 High-Yield Dividend Stocks Paying 5% or More That Are Worth Buying Now"
              },
              {
                "id": 140870596,
                "url": "https://finnhub.io/api/news?id=7619521132f4e9535f0ddd8a08b079e998755e9a131bb77938d463928ac1aac2",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1249993252/image_1249993252.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "PFE",
                "summary": "Read about this month's list of 5 safe large-cap dividend growth stocks trading at discounts, plus two higher-yield lists (up to 8%).",
                "category": "company",
                "datetime": 1783757700,
                "headline": "5 Relatively Secure And Cheap Dividend Stocks, Yields Up To 8% (July 2026)"
              },
              {
                "id": 140870217,
                "url": "https://finnhub.io/api/news?id=e9430d24f3b5e09f0976b4bd1921f93004ae4f0b0216ac2994a3d8c0636e5bf5",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1292440985/image_1292440985.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "PFE",
                "summary": "Pfizer remains an undervalued diversification play, underperforming the benchmark but increasing 2% since prior coverage. Learn why PFE stock is a strong buy.",
                "category": "company",
                "datetime": 1783753771,
                "headline": "Pfizer: The AI Hedge That Pays You To Stay Defensive"
              },
              {
                "id": 140869996,
                "url": "https://finnhub.io/api/news?id=75e51ead01f62b221f77481bd37db37351f0acf4c0fc43ec6f604bb191bde2ab",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1138851310/image_1138851310.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "PFE",
                "summary": "Explore July’s GVAS Dogs: 10 fair-priced, high-yield large-cap dividend stocks with 2027 gain targets, risk notes, and cash-flow flags. Click here to read more.",
                "category": "company",
                "datetime": 1783749717,
                "headline": "July Graham Value All-Stars (GVAS) Emit 10 Beaming Buys"
              },
              {
                "id": 140869867,
                "url": "https://finnhub.io/api/news?id=2b6c7bfad0ead30e2a11cb9e3fd4c4b19f5e32e8fd9b5292dcb4d4862d40a37b",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1303457428/image_1303457428.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "PFE",
                "summary": "Pfizer is undervalued, trading just over 8x 2026 earnings, with improving dividend yield and core business fundamentals. Learn why PFE stock is a buy.",
                "category": "company",
                "datetime": 1783748718,
                "headline": "Pfizer: The Post-Pandemic Turnaround Is Already Underway"
              },
              {
                "id": 140866922,
                "url": "https://finnhub.io/api/news?id=25d7acb47f3ed9eca0886a9f0080884afee31f93b3c3913488146df9acb10ba7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "So far, Pfizer has been an also-ran in the GLP-1 race, but that could change if its long-acting weight-loss medication takes off.",
                "category": "company",
                "datetime": 1783726500,
                "headline": "Is Pfizer on Track to Launch Its Next Lipitor -- This Time in the Weight-Loss Market?"
              },
              {
                "id": 140866267,
                "url": "https://finnhub.io/api/news?id=26e3244142aa4a95ee667d190ef8b87ac2e3c98187e6a72ba0175663304e147f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "AstraZeneca reported a phase III failure for its ATTR-CM drug Wainua, shifting attention to competitors in this rare heart disease segment. The setback directly affects the competitive position of Pfizer, which markets its own ATTR-CM therapy. Investors are assessing how this development could influence future adoption patterns and revenue potential in ATTR-CM. Pfizer, traded as NYSE:PFE, enters this news cycle with its stock at $24.25 and a value score of 4, alongside mixed multi-year...",
                "category": "company",
                "datetime": 1783717872,
                "headline": "Pfizer (PFE) Gets An Opening In ATTR CM After AstraZeneca Trial Failure"
              },
              {
                "id": 140866268,
                "url": "https://finnhub.io/api/news?id=1cb68452ec959511e0de26cf1d033481e2bbfdeabc91133af58123356e235645",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Healthcare stocks were lower late Friday afternoon, with the NYSE Healthcare Index decreasing 0.7% a",
                "category": "company",
                "datetime": 1783713046,
                "headline": "Sector Update: Healthcare Stocks Decline Late Afternoon"
              },
              {
                "id": 140865358,
                "url": "https://finnhub.io/api/news?id=a6c345da42cb5495cd3e934034271daeaace2744ec56febe3c44665ced9066c3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "It’s the right time to jump in on dividend stocks. Clorox, Pfizer, Verizon and Comcast are some of the names to consider.",
                "category": "company",
                "datetime": 1783710960,
                "headline": "Why Verizon, Clorox and More Dividend Stocks Are Flashing a Buy Signal"
              },
              {
                "id": 140864368,
                "url": "https://finnhub.io/api/news?id=be097c16c7af3436fbb9001e84a3df243f9b9fc6b46b42bdfa025492ac285c61",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Pfizer's (PFE) second-quarter revenue is expected to match Wall Street's estimates, while its earnin",
                "category": "company",
                "datetime": 1783701248,
                "headline": "Pfizer Poised for Mixed Second Quarter, RBC Says"
              },
              {
                "id": 140864369,
                "url": "https://finnhub.io/api/news?id=ad20837c0675468d603ed5badbeb4fe0d108fe8ca9df79d9b780074e7fe9efa2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "BridgeBio Pharma hit a 52-week high after a rival's phase III setback boosts confidence in Attruby's competitive position in ATTR-CM.",
                "category": "company",
                "datetime": 1783700460,
                "headline": "How a Rival's Clinical Setback Sent BBIO Stock to a 52-Week High"
              },
              {
                "id": 140864370,
                "url": "https://finnhub.io/api/news?id=35df112b68105371844ecdbfba9e923fb82bf397e49e95b3d9bf90427e05f99a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Pfizer (PFE) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.",
                "category": "company",
                "datetime": 1783699802,
                "headline": "Will Pfizer (PFE) Beat Estimates Again in Its Next Earnings Report?"
              },
              {
                "id": 140863047,
                "url": "https://finnhub.io/api/news?id=4314fc7b5a42947b0f338fd3e32e56c0aeaee63748d601a51a29729bb6bc27f0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "NEW YORK & TOKYO, July 10, 2026--Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, \"Astellas\") today announced that the U.S. Food and Drug Administration (FDA) has approved PADCEV® (enfortumab vedotin-ejfv), a Nectin-4 directed antibody-drug conjugate, plus the PD-1 inhibitor, Keytruda® (pembrolizumab) or Keytruda QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) as neoadjuvant and adjuvant (before and after surgery) treatment for adult patients w",
                "category": "company",
                "datetime": 1783696980,
                "headline": "U.S. FDA Approves PADCEV® plus Keytruda® as Neoadjuvant and Adjuvant Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility"
              },
              {
                "id": 140866551,
                "url": "https://finnhub.io/api/news?id=37ee3b4cd59fbee4a33018cfa0df5ed97931ab70cbc5cccb8992b58f8b59023d",
                "image": "",
                "source": "Benzinga",
                "related": "PFE",
                "summary": "B of A Securities  analyst Jason Gerberry   maintains Pfizer (NYSE:PFE) with a Neutral and lowers the price target from $27 to $26.",
                "category": "company",
                "datetime": 1783692473,
                "headline": "B of A Securities Maintains Neutral on Pfizer, Lowers Price Target to $26"
              },
              {
                "id": 140866552,
                "url": "https://finnhub.io/api/news?id=a43cc21507d7ed002b48d2b9ebcf1f61039e416a336c744ab253ad1644fe369f",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/10/Logo-Pfizer-Inc--Is-An-American-Multinat.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "PFE",
                "summary": "FDA approves Pfizer and Astellas' PADCEV plus Keytruda for muscle-invasive bladder cancer, backed by Phase 3 survival data.",
                "category": "company",
                "datetime": 1783690462,
                "headline": "Pfizer, Astellas Expand PADCEV-Keytruda Label With FDA Nod In Bladder Cancer"
              },
              {
                "id": 140861656,
                "url": "https://finnhub.io/api/news?id=588876ee069e67617c925025ea7cd74589c56bcc654a62507960c8a090509d11",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Both McDonald's and Pfizer are blue-chip laggards trading at a discount, both cut reliable dividend checks, and both promise retirees a place to park serious money. But one of them carries hidden risks that could quietly wreck an income portfolio.",
                "category": "company",
                "datetime": 1783687247,
                "headline": "McDonald’s or Pfizer: One Offers Real Growth, One Just Pays You to Wait"
              },
              {
                "id": 140861555,
                "url": "https://finnhub.io/api/news?id=fe0097a1d1dc84c557427a69c3a73840d1ee31881d8fde66985a82b7b6aaa9cb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "This healthcare giant is on a serious run, but for investors arriving now, the question is whether the price of admission already includes the victory lap.",
                "category": "company",
                "datetime": 1783684953,
                "headline": "JNJ Stock Keeps Climbing. Should You Climb On?"
              },
              {
                "id": 140861696,
                "url": "https://finnhub.io/api/news?id=dc725e5e4b24924ad305d34be9367f78a9032955868bd4201eb6980009b51ac2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Pfizer Inc. (NYSE:PFE) was among the stocks Jim Cramer shared his opinions on during Mad Money. A caller asked for Cramer’s thoughts regarding the stock, and he replied: Okay, they do have earnings growth problems. They haven’t been able to make the Seagen acquisition work the way it should. The dividend is safe at 7%. […]",
                "category": "company",
                "datetime": 1783684902,
                "headline": "Jim Cramer on Pfizer: “I Can’t Come Up With Where the Growth Is”"
              },
              {
                "id": 140860719,
                "url": "https://finnhub.io/api/news?id=6ba326b18f13f774e3be2178a746990fab5ebabf0720aaaace213b57a39dd47e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Shareholders who bet on the industry have been rewarded lately as healthcare stocks have returned 11.5% over the past six months, topping the S&P 500 by 4.3 percentage points.",
                "category": "company",
                "datetime": 1783683320,
                "headline": "1 Healthcare Stock with Solid Fundamentals and 2 We Brush Off"
              },
              {
                "id": 140863471,
                "url": "https://finnhub.io/api/news?id=03e9717fd6226893fba97a753a42c6d3fff5e294c9943fbd38d8619dd2efab27",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/10/Konskie--Poland---ApIonis-Pharmaceutical.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "PFE",
                "summary": "Ionis and AstraZeneca's Phase 3 ATTR-CM trial misses its primary goal, analyst says the outcome favors existing and next-gen therapies.",
                "category": "company",
                "datetime": 1783683043,
                "headline": "Ionis, AstraZeneca Stumble in ATTR-CM Trial as Rivals Stand to Gain"
              },
              {
                "id": 140866554,
                "url": "https://finnhub.io/api/news?id=0b00725854db5ba91841ef9b20f9ce063edae5d99c6c2bbdbafc178fded9a90c",
                "image": "",
                "source": "Benzinga",
                "related": "PFE",
                "summary": "First and only treatment regimen for adults with MIBC, regardless of cisplatin eligibility, representing a platinum-free potential standard of careBroadened approval supported by Phase 3 EV-304 data showing a nearly 50%",
                "category": "company",
                "datetime": 1783682825,
                "headline": "Pfizer And Astellas Win FDA Approval For PADCEV Plus Keytruda As First Platinum-Free Perioperative Treatment For Muscle-Invasive Bladder Cancer"
              },
              {
                "id": 140860720,
                "url": "https://finnhub.io/api/news?id=ba6774f4c797609d78972d269f9dd0e128723ef46ee293f748b530bc565de592",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Pfizer's (PFE) vaccine disputes with Poland and Romania continue, now extending to the countries' ai",
                "category": "company",
                "datetime": 1783682216,
                "headline": "Market Chatter: Pfizer's Vaccine Disputes With Poland, Romania Continue"
              },
              {
                "id": 140865365,
                "url": "https://finnhub.io/api/news?id=335762a1f2f4d8073dffe849222cbd024432cd7ca03a66ee9900ec9ed959ee0e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "AstraZeneca’s shares fell as much as 10.6% in London, which is its largest intraday plummet since 2017, per Bloomberg.",
                "category": "company",
                "datetime": 1783656060,
                "headline": "AstraZeneca Plunges After New Heart Disease Drug Fails Trial"
              },
              {
                "id": 140855845,
                "url": "https://finnhub.io/api/news?id=b3d351adc993be520435759189d72560b105017da985670db5e2dac92e23e062",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "AstraZeneca stock crashed Thursday after its Ionis-partnered treatment for a rare heart disease failed in Phase 3 testing.",
                "category": "company",
                "datetime": 1783628781,
                "headline": "Why AstraZeneca Crashed 6%, Leading Two Rivals, Including Pfizer, To Jump"
              },
              {
                "id": 140853711,
                "url": "https://finnhub.io/api/news?id=032b398ac249490a7fc750ea6c2621e8c34c9262efc9813876f26250b4b531c3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "The U.S. Food and Drug Administration recently expanded approval for Pfizer’s IBRANCE, making it the first CDK4/6 inhibitor maintenance therapy for HR+, HER2+ metastatic breast cancer after induction treatment. This label expansion enhances the commercial and clinical importance of IBRANCE within Pfizer’s oncology franchise at a time when the company faces pressure from upcoming patent expirations and weaker COVID-related revenues. We’ll now examine how this new maintenance indication for...",
                "category": "company",
                "datetime": 1783617353,
                "headline": "Did FDA’s IBRANCE Maintenance Approval Just Shift Pfizer’s (PFE) Oncology-Focused Investment Narrative?"
              },
              {
                "id": 140853712,
                "url": "https://finnhub.io/api/news?id=b2bd8c6450a444d35fdf90da15015ace9f69d206c8068603d591af895b7998ed",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Jim Cramer stared down a stock yielding 7% and sitting near its 52-week low, and still would not tell viewers to buy it. On the July 7 episode of CNBC’s Mad Money, a caller from Orland Park, Illinois pitched Pfizer as an income-and-value setup, and Cramer conceded the case looked tempting. He landed on a ... ‘It Kills Me to Say That’: Cramer Won’t Recommend Pfizer, Even With Its 7% Dividend",
                "category": "company",
                "datetime": 1783614359,
                "headline": "‘It Kills Me to Say That’: Cramer Won’t Recommend Pfizer, Even With Its 7% Dividend"
              },
              {
                "id": 140853484,
                "url": "https://finnhub.io/api/news?id=a37245c725bdaa7038adeca694577bae64e2a1096e408d1811dd4be0d93626e9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "The Health Care Select Sector SPDR Fund (NYSEARCA:XLV) is the default healthcare allocation for millions of investors, and for good reason. XLV owns the entire S&P 500 healthcare complex in one ticker: insurers, device makers, biotech, and Big Pharma. It has returned 21.61% over the past year and 159.84% over ten years. If the reason ... Two Drugmakers Own 90% of the Obesity Boom. One Fund Owns Both for 0.59%",
                "category": "company",
                "datetime": 1783613908,
                "headline": "Two Drugmakers Own 90% of the Obesity Boom. One Fund Owns Both for 0.59%"
              },
              {
                "id": 140852126,
                "url": "https://finnhub.io/api/news?id=018b9f7253bc4e17d4c43637f9d4ef486eb81a27b4c5665faefb42064eb3b9b0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Get paid a guaranteed income now on your Amgen shares, which you keep no matter what, in exchange for agreeing to sell at a price that's already a win.",
                "category": "company",
                "datetime": 1783609118,
                "headline": "Make Your AMGN Shares Pay You 8.7% While You Hold Them"
              },
              {
                "id": 140850812,
                "url": "https://finnhub.io/api/news?id=276e65ac7c5991a39aa9ec7a3758acb5f3ce4bad2e75fab780b4fe5f46f7d0c9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "AbbVie's stock commands a king's ransom, but its performance metrics rule the kingdom, leaving investors to ask if they are buying at the top of the reign.",
                "category": "company",
                "datetime": 1783602824,
                "headline": "ABBV Leads Its Peer Group. You Pay For That"
              },
              {
                "id": 140851010,
                "url": "https://finnhub.io/api/news?id=baad14237a296505b0f589808df734d3452f7c8dbc22fee130edb502eb4c71f1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "AstraZeneca stock crashed Thursday after its Ionis-partnered treatment for a rare heart disease failed in Phase 3 testing.",
                "category": "company",
                "datetime": 1783601672,
                "headline": "Why AstraZeneca Crashed 8%, Leading Three Rivals, Including Pfizer, To Jump"
              },
              {
                "id": 140851011,
                "url": "https://finnhub.io/api/news?id=ba16631660d3a48a5ae531367822bcf906cdafae0322973ac498035a39a0af61",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "AstraZeneca and California-based biotech Ionis Pharmaceuticals announce a late-stage trial failure for their gene silencing drug, Wainua.",
                "category": "company",
                "datetime": 1783601100,
                "headline": "AstraZeneca and Ionis Stocks Sink on Trial Miss and Analysts See an Overreaction"
              },
              {
                "id": 140851012,
                "url": "https://finnhub.io/api/news?id=9d098d0c35c7da1da47ea2eb69d092c9fa0c3e5f1c16e510a0016b77aa5c7dc5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "TORONTO, July 09, 2026--BenchSci, a leading provider of AI software for biopharma research and development, today announced the appointment of Dr. Mikael Dolsten, M.D., Ph.D., as Chairman of its Board of Directors, effective June 2026 — the first Chairman role in the company's history. Dr. Dolsten joined BenchSci's board as a director in July 2025, a year after retiring as Chief Scientific Officer and President of Pfizer Research & Development, where he could have taken a board seat at nearly an",
                "category": "company",
                "datetime": 1783598400,
                "headline": "BenchSci Names Former Pfizer R&D Chief Dr. Mikael Dolsten as Chairman of the Board"
              },
              {
                "id": 140851514,
                "url": "https://finnhub.io/api/news?id=ba024cdd9895c7708abe3ca98f213636ae50da1e97d62de266bad2fd79a3848f",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2197698139/image_2197698139.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "PFE",
                "summary": "Alnylam Pharmaceuticals stands to benefit from the unexpected Phase III failure of Ionis/AstraZeneca’s eplontersen. Read why ALNY stock is a buy.",
                "category": "company",
                "datetime": 1783593830,
                "headline": "Alnylam Pharmaceuticals: An Unexpected Rival Trial Failure Improves The Core TTR Franchise Outlook"
              },
              {
                "id": 140850358,
                "url": "https://finnhub.io/api/news?id=840cbddb211ad3a61dbdba03223eb2cf874f8da5b0b48f025699b494ac5f7406",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2256411028/image_2256411028.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "PFE",
                "summary": "Novo Nordisk regains competitive ground in obesity with the strong launch of the Wegovy pill, reversing some of the recent underperformance against Eli Lilly.",
                "category": "company",
                "datetime": 1783586769,
                "headline": "Novo Nordisk's Wegovy Pill Escalates Eli Lilly Rivalry"
              },
              {
                "id": 140848108,
                "url": "https://finnhub.io/api/news?id=83802d7c0c6cf8398ae3af9cf033877b0a4aec73cbd5ee80e3f87882e6d45d45",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Eli Lilly (LLY) keeps setting records, and Wall Street’s rating of its stock keeps increasing as well. On Tuesday, one of JPMorgan’s most closely watched healthcare stock analysts, Chris Schott, who frequently covers Pfizer Inc. (PFE), Eli Lilly, and Teva Pharmaceutical Industries Ltd. ...",
                "category": "company",
                "datetime": 1783573620,
                "headline": "JPMorgan resets LLY stock target on drug demand"
              },
              {
                "id": 140853229,
                "url": "https://finnhub.io/api/news?id=fce005d26d622395102680065e12d43aeffbb9a90be304e815e5badc41c3e34d",
                "image": "https://image.cnbcfm.com/api/v1/image/108198691-1757936194403-gettyimages-2221649488-Astrazeneca_Office_Building_in_Shanghai.jpeg?v=1760116750&w=1920&h=1080",
                "source": "CNBC",
                "related": "PFE",
                "summary": "A late-stage clinical trial failed to miss its primary endpoint, U.K.'s laregst drugmaker said Thursday.",
                "category": "company",
                "datetime": 1783568048,
                "headline": "AstraZeneca stock drops 9% after heart drug trial miss deals rare blow to pharma powerhouse"
              },
              {
                "id": 140845452,
                "url": "https://finnhub.io/api/news?id=83b05d7ea9501ebcffd979ee1e3ecb29f7a2f8c1cad68e0317792ab69e882a07",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Income investors watching the calendar have a narrow window this week. Three of the market’s most widely held high-yield names are about to lock their next payment rosters, and the buy-by deadlines are close enough that a delayed brokerage order could push readers a full quarter down the line before the next check clears. The ... 3 High-Yield Dividends That Pay You Soon (But You Must Act Quickly)",
                "category": "company",
                "datetime": 1783541247,
                "headline": "3 High-Yield Dividends That Pay You Soon (But You Must Act Quickly)"
              },
              {
                "id": 140843362,
                "url": "https://finnhub.io/api/news?id=597f4902dfd05c08eeacaf56c3d2203bd898010321778f32442a1e1312d5a219",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Major US biopharmaceutical companies' performance in the second half of the year is likely to be dri",
                "category": "company",
                "datetime": 1783529860,
                "headline": "Biopharma Companies' Second-Half Performance to be Largely Driven by Fundamentals, Morgan Stanley Says"
              },
              {
                "id": 140843488,
                "url": "https://finnhub.io/api/news?id=9d90ff2551d2d5004257cbb593ff48f0e618ac0992bc59c659cc691556e0a037",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "BBIO builds on Attruby's launch as rising rare disease diagnoses and late-stage pipeline candidates set up multiple potential U.S. launches.",
                "category": "company",
                "datetime": 1783528080,
                "headline": "BridgeBio Stock Taps Rare Disease Trends and New Diagnosis Growth"
              },
              {
                "id": 140843489,
                "url": "https://finnhub.io/api/news?id=93b440e72e137679f65118af120552914cdb9db6b72a76c74aef27d6d4cb31a0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "BridgeBio Pharma's Attruby sales are surging, but can growth keep justifying its premium valuation amid execution risks and rising costs?",
                "category": "company",
                "datetime": 1783527900,
                "headline": "Is BBIO Stock a Buy Now or Too Expensive for the Risk Ahead"
              },
              {
                "id": 140843490,
                "url": "https://finnhub.io/api/news?id=2ad20f95b9249086624408e0edba856ea10e7dda35497055c104f4c59f3173dc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "BBIO's outlook hinges on Attruby growth, upcoming drug launch catalysts and execution as it seeks to diversify beyond its lone marketed therapy.",
                "category": "company",
                "datetime": 1783527780,
                "headline": "BridgeBio Stock Outlook Hinges on Attruby & New Drug Catalysts"
              },
              {
                "id": 140841778,
                "url": "https://finnhub.io/api/news?id=c1d9e054f88af7cc76ad45c92c50beba49c8aebc5a78167930dc9e5fb87ef4c1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "For shareholders, the coming year isn't about a small gain or loss but a potential journey to one of two very different destinations.",
                "category": "company",
                "datetime": 1783524984,
                "headline": "The Wide Divide Ahead For Eli Lilly Stock"
              },
              {
                "id": 140841826,
                "url": "https://finnhub.io/api/news?id=a50c9d8e99c45c2a53d51a07cc9a2b03e0777db6416ad70b2cf23437194d96c0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Recent interest in Pfizer (PFE) has been driven by U.S. regulators approving IBRANCE as the first CDK4/6 inhibitor maintenance therapy for HR+, HER2+ metastatic breast cancer after induction treatment. This approval opens an additional use for this oncology drug. See our latest analysis for Pfizer. Despite the positive IBRANCE news and a long dividend track record, Pfizer’s recent share price performance has been weak. The stock is down over the past month and quarter, while the 1-year total...",
                "category": "company",
                "datetime": 1783523499,
                "headline": "Is Pfizer (PFE) Undervalued After IBRANCE Won A New FDA Approval?"
              },
              {
                "id": 140841809,
                "url": "https://finnhub.io/api/news?id=9115f15dbec4ba6eb3628f98f8d259cf39b7bdba9b0b5a2a9d5cf1c3e7ac4b64",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "The S&P 500 keeps climbing, up nearly 9% year to date, and yet a handful of large-cap dividend payers are trading like the bull market forgot they exist. That is exactly where opportunity hides in July. If you have $1,000 to put to work, three NYSE-listed names stand out on valuation, cash flow, and payout ... 3 Absurdly Cheap Dividend Stocks to Buy With $1,000 in July",
                "category": "company",
                "datetime": 1783520798,
                "headline": "3 Absurdly Cheap Dividend Stocks to Buy With $1,000 in July"
              },
              {
                "id": 140841828,
                "url": "https://finnhub.io/api/news?id=60d1603a05d70f51082c263012eb67bd5d6759dfcb6f247c03823811a356be76",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Pfizer (PFE) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",
                "category": "company",
                "datetime": 1783515605,
                "headline": "Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know"
              },
              {
                "id": 140840567,
                "url": "https://finnhub.io/api/news?id=65ea2b78b443e26fb34a56819fcdbdd1cc66f1a856204922ccf8ae1b23686e00",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Pfizer Inc. (NYSE:PFE) is one of the dividend stocks picked by financial media as investors ask whether dividend stocks are tax-efficient. On June 24, Pfizer said its board declared a $0.43 third-quarter dividend on the company’s common stock, payable September 1 to holders of record at the close of business on July 24. Pfizer also […]",
                "category": "company",
                "datetime": 1783514929,
                "headline": "How Pfizer’s (PFE) Dividend Record Separates Tax Treatment From Business Momentum"
              },
              {
                "id": 140840466,
                "url": "https://finnhub.io/api/news?id=ba0edb8678292f7637ad16b2934dae337c3ef3760794d05a61f7e4f34e6b582c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Oncology innovation is reshaping cancer care as AI, immunotherapy and targeted therapies fuel pipeline growth and spotlight promising cancer-focused stocks.",
                "category": "company",
                "datetime": 1783513980,
                "headline": "3 Cancer Stocks to Watch as Oncology Innovation Accelerates"
              },
              {
                "id": 140842902,
                "url": "https://finnhub.io/api/news?id=1a2f71857ee982240ad2bedd9c9f798519fe4faf467d1463e02f441c36f7b81c",
                "image": "https://image.cnbcfm.com/api/v1/image/108332131-17835223421783522339-47036321107-1080pnbcnews.jpg?v=1783522341&w=1920&h=1080",
                "source": "CNBC",
                "related": "PFE",
                "summary": "Scott Rechler, chairman and CEO of RXR, joins 'Squawk on the Street' to discuss the buckling high-rise in Manhattan, converting former office buildings into residences and more.",
                "category": "company",
                "datetime": 1783508496,
                "headline": "RXR CEO Scott Rechler on office conversion push"
              },
              {
                "id": 140845356,
                "url": "https://finnhub.io/api/news?id=9aded0979b5fc1c01d4a491dae253a32f0cb4a540e202ec9f8e10ba2748b1604",
                "image": "",
                "source": "Benzinga",
                "related": "PFE",
                "summary": "JP Morgan  analyst Chris Schott   maintains Pfizer (NYSE:PFE) with a Neutral and lowers the price target from $30 to $28.",
                "category": "company",
                "datetime": 1783508280,
                "headline": "JP Morgan Maintains Neutral on Pfizer, Lowers Price Target to $28"
              },
              {
                "id": 140836418,
                "url": "https://finnhub.io/api/news?id=e1fa3e19cc21dbace8a889bebf619d15744ea5c1152d1b2f2e0c8b90f04edfad",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "They may not remain cheap for too much longer.",
                "category": "company",
                "datetime": 1783464600,
                "headline": "2 Dirt Cheap Dividend Stocks to Buy With $1,000 Right Now"
              },
              {
                "id": 140835477,
                "url": "https://finnhub.io/api/news?id=b03613ad52a2bf852782ae88316b0d4f5ca9f28d287f041d33fb5612ca8121d0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Finding stocks with generous dividends isn’t easy these days, and with packaged food giant Conagra recently getting demoted from the S&P 500, Pfizer is now the highest yielding stock in the benchmark index.  The drug company, which has made quarterly payouts more than 80 straight years, is certain to get a lot of attention from dividend hunters.  Pfizer’s high yield reflects investors’ trepidation over the stock.",
                "category": "company",
                "datetime": 1783452780,
                "headline": "2 Healthcare Stocks to Buy for Their Dividends—and Why Pfizer Isn’t One of Them"
              },
              {
                "id": 140835353,
                "url": "https://finnhub.io/api/news?id=c4f382b5352bbe5ca224d50764aeb31d6d4bba886603869762d997d1bc75054d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Construction at  Pfizer’s  former headquarters in Manhattan was halted Tuesday because of crumbling floors and other structural issues.  The problems with the building’s renovation, which the company sold about eight years ago for conversion to apartments, are a metaphor of sorts for Pfizer stock, which began Tuesday with the highest yield in the  index, at more than 7%.  Pfizer stock, which is up 1.6% to $24.10 Tuesday, has been the worst performer among its large-cap U.S. peers during 2026 and over the past 10 years.",
                "category": "company",
                "datetime": 1783452120,
                "headline": "Former Pfizer Building Is Crumbling—Just as the Stock Has"
              },
              {
                "id": 140842604,
                "url": "https://finnhub.io/api/news?id=25b9737c32659b118e6d06e5fd552407615007fb05e58b3082830c3625d38b4e",
                "image": "https://image.cnbcfm.com/api/v1/image/108331765-3ED1-MM-A-070726.jpg?v=1783463497&w=1920&h=1080",
                "source": "CNBC",
                "related": "PFE",
                "summary": "CNBC's Jim Cramer discusses the day's market action, the stocks he's watching and more.",
                "category": "company",
                "datetime": 1783451536,
                "headline": "I find it surprising that so much money was flowing into the hyperscalers: Cramer"
              },
              {
                "id": 140833487,
                "url": "https://finnhub.io/api/news?id=1c6e56e01538f2129725a1a2245a56483aab3fa381ee0e06751530a6743d1d38",
                "image": "https://www.chartmill.com/images/uploads/CM_Most_Active_Stocks_Small_free_fec0650b7f.webp",
                "source": "ChartMill",
                "related": "PFE",
                "summary": "Looking for the most active S&P500 stocks in today's session? Join us as we dive into the US markets on Tuesday and discover the stocks that are dominating the trading activity and setting the pace for the market.",
                "category": "company",
                "datetime": 1783447501,
                "headline": "These S&P500 stocks are the most active in today's session"
              },
              {
                "id": 140832866,
                "url": "https://finnhub.io/api/news?id=cab4113429911de971a850c6643e196f8c2937ce65e17b8eb11e2d422699e893",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Healthcare has been an unloved corner of the market in 2026, but that neglect has created a rare setup: quality names trading in single-digit and low-double-digit territory while still throwing off cash, growing earnings, and reaffirming guidance. For retail investors scanning for value, the sub-$30 shelf in healthcare currently offers exposure to a pending strategic ... 3 Dirt Cheap Healthcare Shares Under $30 to Buy Right Now",
                "category": "company",
                "datetime": 1783444791,
                "headline": "3 Dirt Cheap Healthcare Shares Under $30 to Buy Right Now"
              },
              {
                "id": 140833114,
                "url": "https://finnhub.io/api/news?id=f756293627432faf14cb488eca0a7282ce6023709b0717ee9832737f3076b676",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "A 7% dividend yield will grab your attention, but be sure to read the fine print.",
                "category": "company",
                "datetime": 1783440300,
                "headline": "Opinion: Pfizer's Dividend Is Riskier Than You Might Think"
              },
              {
                "id": 140831295,
                "url": "https://finnhub.io/api/news?id=3f5c10eed8e8606ed043e3df2f6b863e7bcce6f39900fce931d599a7f1c0dcb7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "AZN targets continued 2026 growth with expanding blockbuster medicines, a strong pipeline and 2030 revenue goals as it outpaces Pfizer on key metrics.",
                "category": "company",
                "datetime": 1783429260,
                "headline": "Pfizer or AstraZeneca: Which Stock Offers Better Long-Term Potential?"
              },
              {
                "id": 140830195,
                "url": "https://finnhub.io/api/news?id=9d80ef43b5d93185e9562bcdf1c88c58365a62710c1dcc2c31a9557085e49539",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Healthcare has become Wall Street’s bargain bin in 2026, and value hunters are starting to pay attention. Drug pricing reform, patent cliffs and post-COVID-19 hangovers have crushed multiples across Big Pharma, but the wreckage has created opportunities in two cash-generative franchises trading at single-digit forward earnings multiples. Heading into July, Novo Nordisk and Pfizer stand ... 2 Dirt Cheap Healthcare Stocks to Buy in July",
                "category": "company",
                "datetime": 1783427427,
                "headline": "2 Dirt Cheap Healthcare Stocks to Buy in July"
              },
              {
                "id": 140827916,
                "url": "https://finnhub.io/api/news?id=25504993a6eb4381da6b086591a4e419f4975efc5a39a72aaefcabf94b74db77",
                "image": "",
                "source": "Fintel",
                "related": "PFE",
                "summary": "",
                "category": "company",
                "datetime": 1783410864,
                "headline": "HSBC Downgrades Pfizer (PFE)"
              },
              {
                "id": 140825405,
                "url": "https://finnhub.io/api/news?id=5e30e52a144784a67ba65e26b4eb031695633a604daf470c9ac8781ea2ebe603",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Pfizer (PFE) concluded the recent trading session at $23.72, signifying a -2.47% move from its prior day's close.",
                "category": "company",
                "datetime": 1783374303,
                "headline": "Pfizer (PFE) Stock Sinks As Market Gains: Here's Why"
              },
              {
                "id": 140824417,
                "url": "https://finnhub.io/api/news?id=186fff17d3fd8c74d0ea37961a030197361df88d1472c2d1cb324314c6a059a8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Before the share price caught on, the drugmaker was dealing with a problem most companies only dream of, and it was the clearest sign a surge was building.",
                "category": "company",
                "datetime": 1783369384,
                "headline": "What Eli Lilly Stock Said When It Had Too Much Business"
              },
              {
                "id": 140822960,
                "url": "https://finnhub.io/api/news?id=7f6dadda73094a707158c540764e15eb0531a6e697ba7ba97279949834966388",
                "image": "https://www.chartmill.com/images/uploads/CM_Most_Active_Stocks_Small_free_fec0650b7f.webp",
                "source": "ChartMill",
                "related": "PFE",
                "summary": "Let's have a look at what is happening on the US markets on Monday. Below you can find the most active S&P500 stocks in today's session.",
                "category": "company",
                "datetime": 1783361100,
                "headline": "Explore the S&P500 index on Monday and find out which stocks are the most active in today's session."
              },
              {
                "id": 140822583,
                "url": "https://finnhub.io/api/news?id=a1cfc708dc4e87791be5070950f211a0e8b9d48ad9ed86bfaee9b1c7d09f3ad9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "ALNY's advancing pipeline and partnered programs can expand future revenue sources alongside its growing portfolio of approved therapies.",
                "category": "company",
                "datetime": 1783353300,
                "headline": "Can Alnylam's Drug Pipeline Fuel Its Long-Term Revenue Growth?"
              },
              {
                "id": 140834366,
                "url": "https://finnhub.io/api/news?id=abc10786c5d0f4f18de6845914e601f93e69006be4c5f969c9910cea38526873",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/06/Pharma-Giant-Joins-Initiative.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "PFE",
                "summary": "Pfizer was downgraded to Hold as analysts cited delayed pipeline catalysts, management changes and reduced near-term re-rating potential.",
                "category": "company",
                "datetime": 1783347270,
                "headline": "Pfizer's Growth Story Faces a Wait as Pipeline and Leadership Doubts Mount"
              },
              {
                "id": 140821151,
                "url": "https://finnhub.io/api/news?id=6a00b12582e1165c091f4ba20eacc947aebfa4bf209e1432e7fae8fe2af51de2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Pfizer's IBRANCE has received new FDA approval as the first CDK4/6 inhibitor maintenance therapy for HR+, HER2+ metastatic breast cancer after induction treatment. The approval covers use of IBRANCE in combination with trastuzumab and endocrine therapy for patients with this subtype of breast cancer. The decision is based on results from the Phase 3 PATINA trial. For investors watching Pfizer (NYSE:PFE), this approval adds a fresh clinical milestone to a stock that has faced pressure in...",
                "category": "company",
                "datetime": 1783347059,
                "headline": "Pfizer (PFE) Wins FDA Approval For IBRANCE In HER2 Positive Breast Cancer"
              },
              {
                "id": 140819320,
                "url": "https://finnhub.io/api/news?id=35f52776660d9ec36474180a714ebba89a58bab560a35354ffec23746c014381",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Pre-Market Stock Futures: Futures are trading mixed as we get ready to start the first full week of trading for the third quarter, as traders and investors return from the long 4th of July holiday. With second-quarter earnings starting this week, and with all of the major indices trading at or near all-time highs, you ... Here Are Monday’s Best Wall Street Analyst Research Calls: Agnico Eagle Mines, Datadog, Delta Air Lines, Gilead Sciences, Okta, Pfizer, Regions Financial, T-Mobile, and More",
                "category": "company",
                "datetime": 1783338748,
                "headline": "Here Are Monday’s Best Wall Street Analyst Research Calls: Agnico Eagle Mines, Datadog, Delta Air Lines, Gilead Sciences, Okta, Pfizer, Regions Financial, T-Mobile, and More"
              },
              {
                "id": 140819912,
                "url": "https://finnhub.io/api/news?id=b5d2bd20e0a76d685d7676d5181354c92bbb779edc1b0cc1076343be0a7f6da6",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/628093148/image_628093148.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "PFE",
                "summary": "Discover 5 top Big Pharma stocks amid rising cancer, type 2 diabetes and IMIDs—dividend yields, earnings beats and why they lag AI names. Click for the picks.",
                "category": "company",
                "datetime": 1783331728,
                "headline": "My Top 5 Pharma Stocks Wall Street Ignores"
              },
              {
                "id": 140823076,
                "url": "https://finnhub.io/api/news?id=10e3149e30354dcea9534bcd86613720b4e2e814833ae2d782d9195f342a0b69",
                "image": "",
                "source": "Benzinga",
                "related": "PFE",
                "summary": "Cantor Fitzgerald  analyst Carter Gould   reiterates Pfizer (NYSE:PFE) with a Neutral and maintains $27 price target.",
                "category": "company",
                "datetime": 1783329790,
                "headline": "Cantor Fitzgerald Reiterates Neutral on Pfizer, Maintains $27 Price Target"
              },
              {
                "id": 140821477,
                "url": "https://finnhub.io/api/news?id=743d43840259a92e2562df1f97f04a8d16633d283ef9fc14e9a2cbe9695563d6",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/06/Analysts-Adjust-Progressive-Targets.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "PFE",
                "summary": "Top analysts changed outlook on top names. Visit analyst ratings page for complete view. See opinions on HBAN, PFE, DAL, MTB, BRO stocks.",
                "category": "company",
                "datetime": 1783322347,
                "headline": "This M&T Bank Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday"
              },
              {
                "id": 140823078,
                "url": "https://finnhub.io/api/news?id=41fc41ff5f2568092ca2829a24bef00ad5f930bb3460014eeb28c3b7860c6a66",
                "image": "",
                "source": "Benzinga",
                "related": "PFE",
                "summary": "HSBC  analyst Rajesh Kumar   downgrades Pfizer (NYSE:PFE) from Buy to Hold and lowers the price target from $32 to $28.",
                "category": "company",
                "datetime": 1783317195,
                "headline": "HSBC Downgrades Pfizer to Hold, Lowers Price Target to $28"
              },
              {
                "id": 140815808,
                "url": "https://finnhub.io/api/news?id=ea4577ed58144b2199935239e64da810b772973dadbf2ed89bbc8b35f3d0935e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Pfizer Inc. (NYSE:PFE) is one of the best dividend stocks to buy, according to hedge funds. On June 24, the US Food and Drug Administration approved the use of Pfizer Inc. (NYSE:PFE)’s Ibrance in combination with trastuzumab as a maintenance option for patients with HR-positive, HER2-positive locally advanced or metastatic breast cancer after induction treatment. […]",
                "category": "company",
                "datetime": 1783291882,
                "headline": "Pfizer Inc. (PFE): A Top Dividend Stock to Buy According to Hedge Funds amid Ibrance FDA Milestone"
              },
              {
                "id": 140820581,
                "url": "https://finnhub.io/api/news?id=d78c036b50e519b565344311a0d3db62f47be1f8e694fcce308d14cfbc7f99d2",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/05/Elizabeth-Warren.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "PFE",
                "summary": "Elizabeth Warren warns Trump's law pushed children off Medicaid and CHIP in many states, while also challenging TrumpRx's impact on drug costs.",
                "category": "company",
                "datetime": 1783260507,
                "headline": "Warren Says Trump's Law Pushed 2 Million-Plus Children Off Medicaid, CHIP Across States"
              },
              {
                "id": 140804781,
                "url": "https://finnhub.io/api/news?id=ed6b59910ce862c95cd40b12aaf34010202640c1a9fb28002c12aa3b3cb403ad",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/831753552/image_831753552.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "PFE",
                "summary": "Explore 8 “safer” S&P 500 dividend dogs (VICI, VZ, T, F & more) with strong cash-flow coverage and 2027 upside forecasts—see which to buy now.",
                "category": "company",
                "datetime": 1783129139,
                "headline": "Buy In July: 8 IDEAL 'Safer' S&P 500 DiviDogs"
              },
              {
                "id": 140795063,
                "url": "https://finnhub.io/api/news?id=bdb4fef361ff4d2af9d2c5f525ac4c9fcc523e6e39e215c39c20e90739f4da54",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Could this be the secret to Pfizer's rebound strategy?",
                "category": "company",
                "datetime": 1783027200,
                "headline": "Pfizer's CEO Says His Company Has a \"Very Big Balance Sheet\" to Do Deals. Here's the Perfect Next Acquisition Target for the Pharma Giant"
              },
              {
                "id": 140793956,
                "url": "https://finnhub.io/api/news?id=574d1b3d49bb567c3c862b31bfc81d8f93243913911962c6bf4d9b1bbec3b8f5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "(Bloomberg) -- President Donald Trump made more than 21,000 securities trades in his first year back in office, often in intense bursts tied to market events he created.Most Read from BloombergExxon to Change Name for First Time in Decades After RedomicileMeta Is Planning a Cloud Business to Sell AI Computing PowerGermany Rejects Trump’s Demands for NATO Loyalty to WashingtonRussia Indicates Ukraine Fired Long-Range Ballistic MissileKrafton Agrees to Pay ‘Subnautica 2’ Bonuses as Developer’s CEO",
                "category": "company",
                "datetime": 1783015123,
                "headline": "Trump Financial Disclosure Shows 21,000 Trades in 2025"
              },
              {
                "id": 140792959,
                "url": "https://finnhub.io/api/news?id=ee6da6462659dfa08361afe62be1aecd7ac76b797f01f38b6a14f5d8d0d35fbe",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "The healthcare giant raised its outlook for the year, yet the market is holding back its reward, creating a tense waiting game for investors.",
                "category": "company",
                "datetime": 1783013373,
                "headline": "JNJ Stock Management Sees A Breakout, The Market Sees A Standoff"
              },
              {
                "id": 140800457,
                "url": "https://finnhub.io/api/news?id=999e37fcb927fdc13d87b729a5a78234e62f08588956532f4477a7d73d9c09e3",
                "image": "https://image.cnbcfm.com/api/v1/image/108330302-17830266361783026634-46916365950-1080pnbcnews.jpg?v=1783026635&w=1920&h=1080",
                "source": "CNBC",
                "related": "PFE",
                "summary": "CNBC's \"Fast Money\" team discusses the tech trade, market rotation and more with Michael Farr, chairman at FarrCrest Capital.",
                "category": "company",
                "datetime": 1783012424,
                "headline": "FarrCrest Capital's Farr on the market rotation and tech trade"
              },
              {
                "id": 140795898,
                "url": "https://finnhub.io/api/news?id=1c3d61baa20c671c5661468dfe34f7a12b64ad2ebd08913e49f50389c3362e54",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Haleon has struck a five-year partnership with Microsoft as it looks to expand its AI transformation using Microsoft's Copilot.",
                "category": "company",
                "datetime": 1783010117,
                "headline": "Haleon Just Struck a Five-Year Deal With Microsoft. Here Is What It Means for Haleon Stock."
              },
              {
                "id": 140792961,
                "url": "https://finnhub.io/api/news?id=56ace9e8f9a3601c5c52f7e264cce2da28a30e17b535a2b0bb8be19b8729298e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Five of the biggest names in American pharma just got a deadline from Washington. The House Select Committee on China sent letters this week to Merck (MRK), AbbVie (ABBV), Eli Lilly (LLY), Pfizer (PFE), and Bristol Myers Squibb (BMY), Reuters reported. Lawmakers want each company to explain ...",
                "category": "company",
                "datetime": 1783008180,
                "headline": "House committee investigates Merck, AbbVie over China trials"
              },
              {
                "id": 140791366,
                "url": "https://finnhub.io/api/news?id=a60b16d0d67885632b53f8b7db33b97bba6bda6dfda573e80f8a5eb74776eba9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Passive income is the paycheck that arrives whether you show up or not. Wages depend on a functioning employer, a healthy economy, and the continued willingness of both to keep the seat warm. Dividend income depends on a company writing a check every 90 days, and for a handful of blue chips, that check has ... $500 a Month in These Stocks Will Generate $6,700 in Passive Annual Income",
                "category": "company",
                "datetime": 1783004573,
                "headline": "$500 a Month in These Stocks Will Generate $6,700 in Passive Annual Income"
              },
              {
                "id": 140790254,
                "url": "https://finnhub.io/api/news?id=d8ca063f560a9c7bb37395914ee6bff0ffe0d2dbeaa98009574e9b77ccb49a83",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/155151969/image_155151969.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "PFE",
                "summary": "Ascendis Pharma stock surged on Yorvipath’s blockbuster launch and Yuviwel FDA approval. Read the latest analysis on ASND stock here.",
                "category": "company",
                "datetime": 1782985473,
                "headline": "Ascendis Pharma: Behind The Stock Surge"
              },
              {
                "id": 140791120,
                "url": "https://finnhub.io/api/news?id=233b7ac50abe0742971f1567c47077b52c4ff2476e0bf977d51d0666f74aff41",
                "image": "",
                "source": "Benzinga",
                "related": "PFE",
                "summary": "https://t.co/sFqLF8qeSI",
                "category": "company",
                "datetime": 1782983924,
                "headline": "WHO Director-General Ghebreyesus Says He Considers The Cruise Ship-Linked Hantavirus Outbreak To Be Over"
              },
              {
                "id": 140789093,
                "url": "https://finnhub.io/api/news?id=b49372047c0d1d5515be747da8f25332a49f8c785d5b1b52fd84517f85f27b5e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional pressures that can sometimes lead to overly optimistic forecasts.",
                "category": "company",
                "datetime": 1782982344,
                "headline": "2 of Wall Street’s Favorite Stocks Worth Your Attention and 1 We Turn Down"
              },
              {
                "id": 140780769,
                "url": "https://finnhub.io/api/news?id=1c2f4fbfc651fef953e889a20660b791537068fdd23bbf2136ac930d38984e55",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "These stocks offer high yields, are big names in their respective sectors, and have strong fundamentals.",
                "category": "company",
                "datetime": 1782915600,
                "headline": "Pfizer vs Verizon Communications: Which High-Yielding Dividend Stock Is the Better Buy?"
              },
              {
                "id": 140791144,
                "url": "https://finnhub.io/api/news?id=296da59202b329e94eb30e441728d2248e767c13e8d3682da006e1acea6629a2",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/01/Eli-Lilly-and-Co.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "PFE",
                "summary": "Innovent and Eli Lilly sign a China commercialization deal for Verzenios, expanding patient access while Lilly retains manufacturing.",
                "category": "company",
                "datetime": 1782911358,
                "headline": "Innovent, Eli Lilly Partner to Commercialize Breast Cancer Drug in China"
              },
              {
                "id": 140779454,
                "url": "https://finnhub.io/api/news?id=c366bf379bb1092d995dc3ee85c652cdae1e7867cc61435044d2b9afd2abe1ca",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Medicare's new GLP-1 coverage could expand access to weight-loss drugs, making ETFs a diversified way to tap growth across the obesity treatment market.",
                "category": "company",
                "datetime": 1782907980,
                "headline": "Weight Loss ETFs Poised to Rally as Medicare Greenlights GLP-1 Coverage"
              },
              {
                "id": 140779533,
                "url": "https://finnhub.io/api/news?id=6e09e9087825e36132bb224a4238441552d6736155157f3046fa4af746d2cc59",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Dr. David Hung is pulling multiple financial levers to put Nuvation Bio on strong footing as it advances its oncology drugs.",
                "category": "company",
                "datetime": 1782896745,
                "headline": "Doctor-turned-dealmaker reveals his M&A playbook"
              },
              {
                "id": 140777411,
                "url": "https://finnhub.io/api/news?id=f5b17266fc9bbceea8685aa3f3c9b9257f05c08a3b85c9c3756ac095e2969f8f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Pfizer stock is trading in a range where recent returns have been weak over three years, yet the broader valuation checks still lean cheap and suggest the current share price may not fully reflect the company’s fundamentals. Over the past 3 years, Pfizer has delivered a total return that is down about 21%, which shows how much sentiment has cooled since its pandemic peak. The push into oncology and obesity treatments, including recent IBRANCE progress and weight loss drug development, can...",
                "category": "company",
                "datetime": 1782880257,
                "headline": "Is Pfizer (PFE) Stock Undervalued Despite Mixed Oncology Progress?"
              },
              {
                "id": 140777800,
                "url": "https://finnhub.io/api/news?id=461cbb5b7f58f3554a1150c46860a6a3927cbe341e5f7319b8faf7361fc080af",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1300120223/image_1300120223.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "PFE",
                "summary": "My bullish options sub-portfolio brought 60% annualized ROI since inception, crushing the S&P 500 or some options ETFs. Read more on the strategy here.",
                "category": "company",
                "datetime": 1782875826,
                "headline": "Like My Stock Portfolio, My Bullish Options Portfolio Crushed The Benchmarks"
              },
              {
                "id": 140776272,
                "url": "https://finnhub.io/api/news?id=9c0fa14ab3deddccd179895680d521a7dbabed6cab62d54c701591501aa28659",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Pfizer (PFE) closed at $24.08 in the latest trading session, marking a -1.19% move from the prior day.",
                "category": "company",
                "datetime": 1782855906,
                "headline": "Pfizer (PFE) Stock Declines While Market Improves: Some Information for Investors"
              },
              {
                "id": 140775328,
                "url": "https://finnhub.io/api/news?id=d653bc8b5b5d5d4be7060d73b710c383755317accbe5314353287dcbde08f386",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Nike's (NKE) fiscal fourth-quarter revenue slipped year-over-year, while the sportswear company's ea",
                "category": "company",
                "datetime": 1782853676,
                "headline": "Nike Fourth-Quarter Revenue Slips as Expected Tariff Refunds Boost Earnings"
              },
              {
                "id": 140775329,
                "url": "https://finnhub.io/api/news?id=14ef91b5d318a3c405bb605dba0e995057b6f61b6c65b2bb5e6acb2d627d85de",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Nike stock (NKE) is moving lower in Tuesday's extended-hours trading after reporting mixed results for the sportswear brand's fiscal fourth quarter: while earnings topped estimates, revenue declined 1.1% year-over-year. Morningstar senior equity analyst David Swartz discusses what he was expecting from the earnings release and how Nike's performance is lining up with CEO Elliott Hill's turnaround strategy.",
                "category": "company",
                "datetime": 1782853061,
                "headline": "Nike turnaround is taking longer than CEO Elliott Hill expected: Analyst"
              },
              {
                "id": 140775242,
                "url": "https://finnhub.io/api/news?id=02b91b29d4d6866e764fad5d9b5d883e4c856174563540aa0f7ce0aaf8483c13",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "The healthcare giant is making waves, but its true value for investors lies in how little it moves with the market.",
                "category": "company",
                "datetime": 1782851051,
                "headline": "Why Is JNJ Stock Defying The Market’s Daily Mood Swings?"
              },
              {
                "id": 140773944,
                "url": "https://finnhub.io/api/news?id=1ced7bb16d986dbc5d54041d714c9881556f83d762c9209f572bdb225bda7c90",
                "image": "https://www.chartmill.com/images/uploads/CM_Most_Active_Stocks_Small_free_fec0650b7f.webp",
                "source": "ChartMill",
                "related": "PFE",
                "summary": "Stay informed about the most active stocks in the S&P500 index on Tuesday's session. Discover the stocks that are generating the highest trading volume and driving market activity.",
                "category": "company",
                "datetime": 1782842700,
                "headline": "Looking for the most active stocks in the S&P500 index on Tuesday?"
              },
              {
                "id": 140773408,
                "url": "https://finnhub.io/api/news?id=8fb61dd33fcbbb335ced32a5c70432f74c400c32d98a99a75027e78a574e6083",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Volatility can lower the cost of entry into businesses that throw off real cash, even as investors recognize that a low share price alone is no guarantee of a bargain. Heading into the back half of 2026, three blue-chip names trading well below the $45 mark stand out for the same reason: predictable cash flows, ... 3 Dirt-Cheap Stocks Under $45 Built to Outperform in a Volatile Market",
                "category": "company",
                "datetime": 1782838057,
                "headline": "3 Dirt-Cheap Stocks Under $45 Built to Outperform in a Volatile Market"
              },
              {
                "id": 140773471,
                "url": "https://finnhub.io/api/news?id=b60fbb2c0ce1fb45c8387013f66392ad1bc0f85028dedac5e289199b0afaea57",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "A bipartisan group of United States lawmakers has opened national security investigations into whether five major pharmaceutical companies, including Merck and AbbVie, were involved in clinical trials conducted in China that may have supported the country’s military capabilities, according to a...",
                "category": "company",
                "datetime": 1782836340,
                "headline": "Merck, AbbVie probed by US lawmakers over China clinical trials: report"
              },
              {
                "id": 140773586,
                "url": "https://finnhub.io/api/news?id=c6e0476e59592a8485924005735032a5f4d376a379161dc1a98916283d89ca89",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "I keep buying Pfizer (NYSE:PFE) every time my brokerage cash builds up, and I am not slowing down. The market is treating this company like a value trap because COVID revenue is rolling off. I am treating it like a cash machine that just bought itself three extra years of patent life on one of ... Wall Street Walked Away From This Powerhouse Stock, But I Am Buying It on Repeat",
                "category": "company",
                "datetime": 1782836145,
                "headline": "Wall Street Walked Away From This Powerhouse Stock, But I Am Buying It on Repeat"
              },
              {
                "id": 140773587,
                "url": "https://finnhub.io/api/news?id=b14d8a4a4df572ec5dd36dfce74c378ba4cad7af2cf47b716a9de2ed4398ade2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "CorMedix broadens beyond DefenCath with Melinta assets, Rezzayo potential and cost synergies as reimbursement changes test long-term earnings durability.",
                "category": "company",
                "datetime": 1782832200,
                "headline": "CRMD's Growth Story Expands Beyond DefenCath Into New Trends"
              },
              {
                "id": 140773588,
                "url": "https://finnhub.io/api/news?id=101ff63855217fab4b5803347ce8c248c613db66414f4095edbfe0a3476860c6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "CorMedix posted surging DefenCath-led revenue and stronger profitability, but reimbursement changes and execution risks could shape the stock's next phase.",
                "category": "company",
                "datetime": 1782832020,
                "headline": "Is CRMD Stock a Buy Now After Strong Growth and New Risks?"
              },
              {
                "id": 140773589,
                "url": "https://finnhub.io/api/news?id=1f5cd482979b12c032cde218cf3a01b6bbe8baa4f5c4638d4e7163e6b4796234",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "CorMedix is shifting from a single-product launch story as DefenCath drives revenue and Rezzayo adds long-term potential despite reimbursement headwinds.",
                "category": "company",
                "datetime": 1782831840,
                "headline": "CRMD Stock Outlook as DefenCath and Rezzayo Expand Growth Path"
              },
              {
                "id": 140774085,
                "url": "https://finnhub.io/api/news?id=f82c597c7b0224650e59ddbedd837ca5b0705ff6b4b1e9f677918cb5b2ffc780",
                "image": "",
                "source": "SeekingAlpha",
                "related": "PFE",
                "summary": "",
                "category": "company",
                "datetime": 1782829958,
                "headline": "Viking Therapeutics: Updating Pipeline Potential As Oral GLP‑1s Accelerate"
              },
              {
                "id": 140772056,
                "url": "https://finnhub.io/api/news?id=5c33c56afc99cbd67b46aaafc8b0fc05e55af3c6785fb391097adb51275ff502",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "Few large-cap dividends generate as much skepticism as Pfizer (NYSE:PFE). The stock trades at $24.37, and the COVID franchise erosion has been brutal, with Comirnaty down 59% and Paxlovid down 63% in Q1 2026. Yet the dividend keeps coming. I want to know if that 7.27% yield is a gift or a warning. The Dividend ... This 7% Yielding Healthcare Powerhouse Belongs in Retirees’ Portfolios",
                "category": "company",
                "datetime": 1782827441,
                "headline": "This 7% Yielding Healthcare Powerhouse Belongs in Retirees’ Portfolios"
              },
              {
                "id": 140771834,
                "url": "https://finnhub.io/api/news?id=8dde04ddcab7fa50ac6d1569beb5d10e4aa9a73a0a05a6d7b7b82f65248f4c2b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "PFE",
                "summary": "It could prove to be a case of better later than never for the healthcare giant.",
                "category": "company",
                "datetime": 1782825600,
                "headline": "Why Pfizer Could Prove to Be an Underrated GLP-1 Stock"
              },
              {
                "id": 140781955,
                "url": "https://finnhub.io/api/news?id=ba88807cf0ccddc6b8093e62c38c465ae13314ab73df98fc19ad55fdd94af86e",
                "image": "https://image.cnbcfm.com/api/v1/image/108297266-1777127244178-gettyimages-2272978539-anotherday208771149_942vh80l.jpeg?v=1777127293&w=1920&h=1080",
                "source": "CNBC",
                "related": "PFE",
                "summary": "Nike was expected to report another quarter of declining sales as the sneaker giant struggles to regain strength under its turnaround strategy.",
                "category": "company",
                "datetime": 1782820801,
                "headline": "Nike results top estimates even as China sales drop 12%; retailer expects $986 million tariff refund"
              },
              {
                "id": 140772368,
                "url": "https://finnhub.io/api/news?id=3baa0b6d8130b52153c4c742a502edc285b76c9502f66aef88dfb9d8fc3d6dd9",
                "image": "",
                "source": "Benzinga",
                "related": "PFE",
                "summary": "- Reuters ",
                "category": "company",
                "datetime": 1782813049,
                "headline": "U.S. House Committee Sends Letters To Pfizer, Eli Lilly & Bristol Myers Squibb Probing China Drug Trials"
              },
              {
                "id": 140772314,
                "url": "https://finnhub.io/api/news?id=e10497ea38e4fbad71eb7072d597a29bb43582fc3c78ed5ce80d21a5cf7c2964",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2194222148/image_2194222148.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "PFE",
                "summary": "Vertex Pharmaceuticals Incorporated offers predictable CF cash flows and pipeline catalysts in pain, hematology & renal (Pove for IgAN). Click for this VRTX update.",
                "category": "company",
                "datetime": 1782810196,
                "headline": "Vertex Pharmaceuticals Has One Of The Widest And Most Durable Moats In Biotech"
              },
              {
                "id": 140781725,
                "url": "https://finnhub.io/api/news?id=cf3205279fea17c3900bbcdfba512aa037db7930700fa3d1e1c2b96b21bcb244",
                "image": "https://image.cnbcfm.com/api/v1/image/108328650-17828230041782823001-46866699601-1080pnbcnews.jpg?v=1782823003&w=1920&h=1080",
                "source": "CNBC",
                "related": "PFE",
                "summary": "Former FDA Commissioner Dr. Scott Gottlieb joins 'Squawk Box' to discuss the FDA's selection of seven companies for its PreCheck Pilot Program, concerns over drug trials in China, and more",
                "category": "company",
                "datetime": 1782808861,
                "headline": "Dr. Scott Gottlieb on concerns over drug trials in China"
              }
            ],
            "data_source": "finnhub_news_keyword_model",
            "article_count": 8,
            "negative_hits": 0,
            "positive_hits": 2,
            "recomputed_at_score": true,
            "sentiment_score_raw": 0.6,
            "source_article_count": 239,
            "discarded_article_count": 211
          },
          "sentimentPoints": 4
        }
      },
      "技術信號": {
        "max": 30,
        "raw": 20.1,
        "grade": "一般",
        "items": {
          "bbPoints": 3,
          "adxPoints": 3,
          "sarPoints": 2.4000000000000004,
          "vcpPoints": 2.2,
          "macdPoints": 4,
          "vcpPayload": {
            "vcp_pass": false,
            "vcp_score": 2.2,
            "vcp_reason": "波幅收縮(10.7%→4.9%)；跌縮量(近10日5日)；靠近20日高位；Ready=Y；Confirm=N",
            "vcp_metrics": {
              "up_days": 4,
              "vol_ref": 47006143.333333336,
              "down_days": 5,
              "vcp_ready": true,
              "above_ma50": false,
              "avg_vol_10": 37309790,
              "avg_vol_20": 40056980,
              "avg_vol_30": 47006143.333333336,
              "range_pct_10": 0.048574869530309005,
              "range_pct_20": 0.08149337615415486,
              "range_pct_30": 0.10678442392613409,
              "up_expand_ok": false,
              "lookback_used": 59,
              "near_20d_high": true,
              "contraction_ok": true,
              "down_shrink_ok": true,
              "up_expand_days": 1,
              "breakout_20d_ok": false,
              "vol_ratio_10_30": 0.7937215724214204,
              "dist_to_20d_high": 0.028849902534113,
              "down_shrink_days": 5,
              "breakout_level_20d": 25.65,
              "vcp_breakout_confirm": false,
              "contraction_ratio_10_30": 0.45488721804511173
            },
            "vcp_name_en": "Volatility Contraction Pattern",
            "vcp_name_zh": "波動收縮形態",
            "vol_contraction": true
          },
          "kdjAdxPoints": 0.5,
          "rsiKdjPoints": 2.4,
          "volumeWeight": 2,
          "maCrossPoints": 0,
          "shortRsiPoints": 0.8,
          "shortMacdPoints": 0.4,
          "volConfirmPoints": 0.6,
          "volumePointsTechnical": 0.8
        }
      },
      "風險管理": {
        "max": 10,
        "grade": "良好",
        "items": {
          "position": {
            "score": 1.8,
            "details": {
              "atrPct": 1.9871537535126456,
              "turnoverUsdM": 924.47200135,
              "liquidityPoints": 0.6,
              "volatilityPoints": 1.2
            }
          },
          "rrPoints": 1.4,
          "stopLevels": {
            "symbol": "US.PFE",
            "rr_range": "1:1.0-1:2.5",
            "risk_profile": "中等",
            "stop_loss_price": 23.92,
            "strength_details": {
              "ma_score": 1,
              "atr_score": 2.5,
              "rsi_score": 2,
              "macd_score": 3,
              "volume_score": 1
            },
            "market_adjustment": 1,
            "risk_reward_ratio": 1.3,
            "stop_loss_percent": 4,
            "take_profit_price": 26.1555,
            "target_multiplier": 1.9,
            "technical_strength": 1.92,
            "take_profit_percent": 5
          },
          "positionPoints": 1.8,
          "stopLossPoints": 2.4,
          "diversification": {
            "score": 2,
            "details": {
              "method": "sector concentration proxy; no portfolio holdings used",
              "sector": "Health Care",
              "concentratedSectorPenalty": 0
            }
          },
          "riskRewardRatio": 1.2580808080808081,
          "stopLossPercent": 3.974307507025291,
          "diversificationPoints": 2
        }
      }
    }
  },
  "modelVersion": "cursor_18_27_news_v2_160",
  "providerErrors": [],
  "rankingScoreMax": 160,
  "dataCompleteness": {
    "complete": true,
    "missingFields": [],
    "optionalInputs": [
      "institutionalData"
    ],
    "requiredInputs": [
      "fundamentals",
      "marketContext.VIX",
      "marketContext.SPY",
      "marketContext.QQQ",
      "catalystData",
      "sentimentData",
      "ATR",
      "sector"
    ],
    "optionalInputWarnings": []
  },
  "technicalIndicators": {
    "adx": 92.86,
    "atr": {
      "atr": 0.495,
      "rule": "ATR / current price; lower volatility scores higher",
      "score": 8,
      "atr_pct": 1.99
    },
    "cci": {
      "rule": "Cursor_18.24 CCI bands",
      "level": "平衡",
      "score": 6,
      "value": 33.34
    },
    "cmf": {
      "rule": "Cursor_18.24 CMF bands",
      "level": "派發",
      "score": 2,
      "value": -0.1187
    },
    "kdj": {
      "d": 50.5,
      "j": 48,
      "k": 49.67,
      "rule": "Cursor_18.24 K/D cross",
      "score": 0,
      "signal": "死叉"
    },
    "mfi": {
      "rule": "Cursor_18.24 MFI bands",
      "level": "入貨中",
      "score": 8,
      "value": 62.39
    },
    "obv": {
      "rule": "Cursor_18.24 recent_slope vs previous_slope",
      "score": 2,
      "trend": "資金流出",
      "value": -259514785,
      "recentSlope": -2158398.5,
      "previousSlope": -37570
    },
    "rsi": 59.64,
    "sar": {
      "rule": "Cursor_18.24 Parabolic SAR",
      "score": 8,
      "trend": "上升",
      "value": 24.5401,
      "position": "SAR喺價下",
      "distancePct": 1.48,
      "previousTrend": "上升"
    },
    "ma50": 25.0978,
    "macd": {
      "macd": 0.02079171240943367,
      "trend": "強烈看漲",
      "signal": -0.0675383208948485,
      "histogram": 0.08833003330428217
    },
    "vwap": {
      "rule": "Cursor_18.24 VWAP 20D consecutive close",
      "score": 10,
      "value": 24.6218,
      "position": "連續5日>VWAP",
      "consecutiveAbove": 12
    },
    "volume": {
      "rule": "Cursor_18.24 volume ratio",
      "level": "無力",
      "ratio": 0.94,
      "score": 4,
      "avgVolume": 39443344,
      "currentVolume": 37112485
    },
    "derived": {
      "ma20": 24.618,
      "ma50": 25.0978,
      "prevClose": 25.15,
      "avgVolume10": 36022039,
      "avgVolume20": 39443344,
      "changePercent": -0.95,
      "avgVolumeForScore": 39443344
    },
    "ma_cross": {
      "ma20": 24.618,
      "ma50": 25.0978,
      "rule": "Cursor_18.24 MA20/MA50 cross",
      "cross": "熊勢",
      "score": 0,
      "prevMa20": 24.5665,
      "prevMa50": 25.1062,
      "spreadPct": 1.91,
      "isVolumeBreakout": false
    },
    "bollinger": {
      "lower": 23.7694,
      "upper": 25.4666,
      "position": "上半部"
    },
    "rsi_short": 52.63,
    "macd_short": {
      "macd": 0,
      "trend": "中性",
      "signal": 0,
      "histogram": 0
    },
    "volume_ratio": {
      "ratio": 0.94
    }
  }
}

{
  "close": 24.91,
  "volume": 37112485,
  "changePercent": -0.95
}